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ABSTRACT
Mammalian circadian rhythms are controlled by a clock located in the
suprachiasmatic nucleus (SCN). The mechanisms through which light phaseshifts the SCN circadian clock are similar to those underlying memory formation
and long-term potentiation (LTP). Several secreted proteins, including tissue-type
plasminogen activator (tPA), plasminogen, and brain-derived neurotrophic factor
(BDNF), have been implicated in this process.

These same proteins are

important for photic phase-shifts of the SCN circadian clock. Early night
glutamate application to SCN containing brain slices resets the circadian clock.
Our experiments find that the endogenous tPA inhibitor, plasminogen activator
inhibitor 1(PAI-1), blocked these shifts in slices from wildtype mice but not mice
lacking its stabilizing protein, vitronectin (VN). Plasmin, but not plasminogen,
prevented inhibition by PAI-1. Both plasmin and active BDNF reversed alpha2antiplasmin inhibition of glutamate-induced shifts. Alpha2-Antiplasmin decreased
the conversion of inactive to active BDNF in the SCN. Both tPA and BDNF
allowed daytime glutamate-induced phase-resetting. Together, these data are
the first to demonstrate expression of these proteases in the SCN, their
involvement in modulating photic phase-shifts, and their activation of BDNF in the
SCN, a potential ‘gating’ mechanism for photic phase-resetting.
Using western-blot analyses of SCN tissue maintained in vitro, we find higher
tPA, plasmin and mBDNF levels in the SCN at night vs. the day. Also, in vitro
glutamate treatment of SCN tissue during early night increases tPA levels to ~2.5
iv

times control levels, while similar treatments during late night and mid-day do not
alter tPA expression. Glutamate treatment in the early night does not alter PAI-1,
plasmin and BDNF levels. Co-treatment with glutamate and PAI-1 decreases
plasmin levels (vs. glutamate treatment alone), while co-treatment with glutamate
and alpha2-antiplasmin decreases the amount of pro- and mBDNF in the SCN
relative to glutamate treatment alone. We also show that mBDNF levels are
significantly lower in tPA knockout mice during both day and night. Together,
these results support circadian clock modulation of BDNF and fibrinolytic protein
levels in the SCN. They also suggest that glutamate modulates tPA expression in
the SCN, while tPA and plasmin modulate BDNF expression.

v

TABLE OF CONTENTS
Chapter

Page

CHAPTER I ........................................................................................................... 1
Background ........................................................................................................... 1
Suprachiasmatic Nucleus (SCN) and Circadian Rhythms ................................. 1
Enhancement of Glutamate Signaling by BDNF and PSA-NCAM ..................... 6
Activation of BDNF by Fibrinolytic Proteins ..................................................... 10
CHAPTER II ........................................................................................................ 16
Tissue-type Plasminogen Activator-Plasmin-BDNF Modulate Glutamate-induced
Phase-shifts of the Mouse Suprachiasmatic Circadian Clock in vitro.................. 16
Abstract ........................................................................................................... 16
Introduction ..................................................................................................... 17
Materials and methods .................................................................................... 19
Brain slice preparation ........................................................................... 19
Drug treatments ..................................................................................... 20
Single-unit recording and data analysis ................................................. 20
Western blots ......................................................................................... 21
Results ............................................................................................................ 22
Expression of fibrinolytic proteins and BDNF in the SCN ...................... 22
Glutamate-induced phase delays are blocked by PAI-1 ........................ 25
Glutamate-induced phase delays are blocked by PAI-1 ........................ 26
Glutamate-induced phase delays are blocked by PAI-1 ........................ 27
Plasmin activation of BDNF is necessary for glutamate-induced phase
delays .................................................................................................... 29
Plasmin activation of BDNF is necessary for glutamate-induced phase
delays .................................................................................................... 32
Involvement of tPA-plasmin-BDNF in late subjective night phase advances
............................................................................................................... 33
BDNF acts as a gating molecule for photic phase-resetting .................. 36
VN is necessary for PAI-1 actions in the SCN ....................................... 38
Discussion ....................................................................................................... 40
CHAPTER III ....................................................................................................... 49
Endogenous and Glutamate-Modulated Fibrinolytic Protein and BDNF
Expression in the Mouse Suprachiasmatic Nucleus in vitro ................................ 49
Abstract ........................................................................................................... 49
Introduction ..................................................................................................... 50
Materials and Methods .................................................................................... 52
Brain slice preparation ........................................................................... 52
Drug treatments ..................................................................................... 53
Western blots ......................................................................................... 54
vi

Statistical analysis ................................................................................. 55
Results ............................................................................................................ 55
In vitro expression patterns of BDNF and fibrinolytic proteins in the SCN55
In vitro modulation of SCN protein expression ....................................... 65
BDNF expression in the SCN of tPA knockout mice .............................. 65
Discussion ....................................................................................................... 69
CHAPTER IV ................................................................................................... 78
Conclusions and Future Directions ..................................................................... 78
A Working Model for Glutamate-induced Phase Shifts in mouse SCN............ 78
BDNF Could Regulate the Expression/activity of NMDA Receptors................ 78
BDNF Effects on Presynaptic Cells ................................................................. 81
BDNF mRNA Alternatives ............................................................................... 82
Localization of Fibrinolytic Proteins and Their Activity ..................................... 83
Plasmin-independent Effects of tPA ................................................................ 84
Neuroserpin ..................................................................................................... 85
LIST OF REFERENCES ..................................................................................... 87
Vita...................................................................................................................... 99

vii

LIST OF FIGURES
Figure

Page

Figure 1.. ............................................................................................................. 11
Figure 2.. ............................................................................................................. 15
Figure 3.. ............................................................................................................. 28
Figure 4. .............................................................................................................. 30
Figure 5.. ............................................................................................................. 31
Figure 6. .............................................................................................................. 34
Figure 7.. ............................................................................................................. 37
Figure 8. .............................................................................................................. 39
Figure 9. .............................................................................................................. 42
Figure 10.. ........................................................................................................... 58
Figure 11. ............................................................................................................ 59
Figure 12. ............................................................................................................ 60
Figure 13. ............................................................................................................ 61
Figure 14. ............................................................................................................ 62
Figure 15. ............................................................................................................ 63
Figure 16. ............................................................................................................ 64
Figure 17 ............................................................................................................. 66
Figure 18. ............................................................................................................ 67
Figure 19. ............................................................................................................ 70
Figure 20. ............................................................................................................ 71
Figure 21. ............................................................................................................ 71

viii

CHAPTER I
Background
Suprachiasmatic Nucleus (SCN) and Circadian Rhythms
Circadian rhythms are biological activities that oscillate under constant
environmental conditions with a period length close to 24 hours. The
endogenously driven circadian rhythms regulate the biological processes of
diverse organisms ranging from prokaryotes to mammals (Kondo and Ishiura,
2000; Sharma, 2003). Patterns of brain wave activity, hormone production, cell
regeneration and other biological activities are all linked to this 24-hour cycle
(Rivkees and Hao 2000).
Circadian rhythms have three key properties that can serve as defining
criteria: first, persistence of an overt rhythm in constant conditions with an
approximately 24h period; second, temperature compensation—that is, freerunning circadian period lengths in an organism are very similar when measured
under different ambient temperatures; third, the endogenous rhythms can be
entrained by certain environmental cues. Under entrainment conditions, the
period of the overt rhythm equals the period of the entraining cycle and the
rhythm maintains a stable phase relationship with the entraining cycle. Also, if
returned to constant conditions, the free-running rhythm continues with a phase
determined by the entraining cycle.
Multiple environmental factors, including light-dark cycles, temperature
cycles, or other stimuli such as social interaction can serve as entraining cues.
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Among them, the most important cue is the 24h solar cycle. Light pulses or
transition between light and darkness can shift almost all circadian rhythms when
applied during certain phases (Reppert and Weaver 2000).
In mammals, the primary circadian clock is located in the suprachiasmatic
nucleus (SCN) of the hypothalamus (Moore and Eichler 1972; Stephan and
Zucker 1972). The SCN is located at the base of the third ventricle, dorsal to the
optic chiasm. Based largely on peptide expression and neural connectivity, the
SCN is divided into two main regions: the core and the shell (Moga and Moore,
1997; Leak et al., 1999). The core is located adjacent to the optic chiasm,
whereas the shell is the dorsal-medial border surrounding the core (Moore et al.,
2002).

Despite

inter-species

differences

and

overlapping

expression,

vasopressin (VP) and vasoactive intestinal polypeptide (VIP) immunoreactive
neurons are generally located in the shell and core SCN, respectively (reviewed
by Moore et al., 2002; Morin and Allen, 2006).
Individual SCN neurons are self-sustained clocks. Both core and shell
neurons exhibit circadian rhythms in electrical activity and gene expression in
cultured brain slices as well as in dissociated cell culture. Although discrete SCN
neurons in culture still display circadian rhythms in electrical activity, they usually
become desynchronized (Welsh et al., 1995). It is thought that synchronization
may involve the release of neurotransmitters such as GABA, as well as other
electrical or chemical signals (Colwell 2000; Liu and Reppert 2000).
Anatomical studies have shown that the SCN receives input from several
sources, including the retina, the intergeniculate leaflet (IGL) and the raphe
2

nuclei. Although the IGL and raphe inputs play important roles in modulating the
SCN clock, SCN clock phase is regulated primarily by the retinal input.
Interestingly, conventional photoreceptors in retinal rod and cone cells are
unnecessary for photoentrainment, since mutant mice lacking rods and cones
are capable of normal photoentrainment (Freedman et al., 1999). These and
other studies led to the discovery of a third class of photoreceptors that is not
involved in visual image formation, melanopsins. Melanopsins are expressed in a
subset of retinal ganglion cells (RGCs). Melanopsin knockout mice show
attenuated light-induced phase shifting, and fail to show pupil constriction in
response to light (Panda et al., 2002; Lucas et al., 2003). Photic signals are
sensed by melanopsin-containing retinal ganglion cells that synapse onto SCN
core neurons, where they secrete the neurotransmitter glutamate (Aronson et al.,
1993; Moore et al., 2002). More recently, it has been shown that SCN neurons
display some transient light adaptation properties, suggesting that input from
rods and cones can also influence SCN neuronal activity (Drouyer et al., 2007).
The light-induced glutamate release in the SCN can reset clock phase when
light occurs during the subjective night, inducing delays in the early night and
advances in the late night. These responses of the SCN clock to photic stimuli
can be mimicked by brief application of glutamate in vitro to SCN-containing
brain slices. SCN neurons express ionotropic AMPA and NMDA receptors, which
are activated by glutamate (Ebling 1996). Application of NMDA replicates the
phase-shifting response generated by glutamate application (Ding et al., 1994).
Conversely, blocking NMDA receptors prevents photic phase shifts (Ding et al.,
3

1994). Together, these data show that glutamate transmits light signals from the
retina to the SCN primarily through activation of NMDA receptors.
Ca2+ influx through NMDA receptors serves as a second messenger that
activates various enzymes within the cell, including nitric oxide synthase (NOS).
Local administration of the NOS inhibitor, L-NAME, in the SCN blocks glutamateinduced phase shifts (Ding et al., 1994; Weber et al., 1995). Therefore, it is
hypothesized that after glutamate binds to NMDA receptors, NOS is activated
and its product, NO, participates in glutamate-induced phase shifts.
The signaling pathway underlying glutamate-induced phase shifts diverges
depending on the time of stimulation. In the late night, NO activates guanylate
cyclase, generating cGMP and activating cGMP-dependent protein kinase
(PKG). This NO/cGMP/PKG pathway has been shown to induce phase advances
in vitro (Ding et al., 1998). In the early night, on the other hand, NO is suggested
to interact with ryanodine receptors (RyR) located on the endoplasmic reticulum
to induce phase delays (Ding et al., 1998). Pre-treatment of RyR inhibitors to the
SCN in the early night blocks glutamate-induced phase delays. Those inhibitors
have no effect on the phase shifts induced during late night (Ding et al., 1998).
These signaling processes are summarized in Figure 1.
Although the signal pathways downstream of NO diverge between early and
late night, they both involve the mitogen-activated protein kinase (MAPK)
cascade and activation of the gene transcription factor, cAMP response element
binding protein (CREB), in SCN neurons (Ginty et al., 1993; Ding et al., 1997).
Binding of CREB to its target, cAMP response element (CRE), on the
4

chromosome triggers transcriptional activation of clock genes. The protein
products of clock genes make up an autoregulatory negative feedback loop that
sustains circadian oscillations (see review, Reppert and Weaver, 2001; Hastings
et al., 2003). In mammals, the positive component of the feedback loop is the
heterodimer of Clock and Bmal1 proteins. Binding of the heterodimer to E-box
motifs in promoter segments stimulates transcription of clock genes. The
negative component of the loop are the products of three Period (Per) and two
Cryptochrome (Cry) genes. The Cry and Per proteins also form heterodimers and
enter the nucleus. During the negative feedback phase, Per/Cry complexes bind
to and inhibit Clock/Bmal1 activity, thereby down-regulating the transcription of
clock genes including their own. The ensuing decline in Cry and Per protein
levels eventually leads to reactivation of Clock/Bmal1-induced clock gene
transcription and reinitiation of the cycle.
Rhythmic clock gene expression probably underlies the rhythmic electrical
activity of SCN neurons (de Jeu et al., 1998; Schaap et al., 1999). It is possible
that there is direct transcriptional regulation of ion channel proteins or regulatory
factors affecting channel activity by CLOCK/BMAL1. Clock genes may also
regulate electrical activity indirectly via clock controlled genes (CCGs), such as
vasopressin (VP) (Jin et al., 1999). VP appears to augment the magnitude of the
electrical activity rhythm in the SCN through a receptor-mediated excitation of
SCN neurons (Mihai et al., 1994; Ingram et al, 1996).
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Enhancement of Glutamate Signaling by BDNF and PSA-NCAM
NMDA receptor activity is modulated by a number of intracellular and
extracellular factors. In particular, phosphorylation of various NMDA receptor
subunit residues can enhance NMDA signaling. For example, a Src-family
tyrosine kinase, Fyn, is expressed abundantly in neurons and associated with
NMDA receptors (Salter 1998). The NMDA receptor subunit NR2A is tyrosinephosphorylated when coexpressed with Fyn (Tezuka et al. 1999). It has also
been shown that phosphorylation of NR2B at Tyr-1472 by Fyn is important for
synaptic plasticity (Nakazawa et al. 2001). Brain-derived neurotrophic factor
(BDNF) is another potent modulator of synaptic plasticity. Previous studies report
that BDNF promotes phosphorylation of NR1 and NR2B, which results in an
enhancement of NMDA receptor activity (Suen et al., 1998; Levine et al. 1998;
Lin et al. 1998). The blockade of NR2B subunit phosporylation prevents BDNFinduced enhancement of glutamatergic neurotransmission (Crozier et al. 1999).
Fyn plays a critical role in BDNF-enhanced NMDA activity, since BDNFdependent phosphorylation is abolished in Fyn knockout mice (Xu et al. 2006).
Fyn has Src homology 2 (SH2) domains, which are supposed to bind to both
NMDA receptors and the phosphorylated BDNF receptor, TrkB (Iwasaki et al.,
1998). Collectively, these results suggest that BDNF enhances phosphorylation
of NMDA subunits through activation of Fyn, leading to altered NMDA receptor
activity and increased synaptic transmission.
In the hippocampus, BDNF is synthesized as a precursor called proBDNF,
which is cleaved by plasmin to generate mature BDNF (mBDNF) (Li et al., 2002;
6

Lu, 2003). BDNF and TrkB are co-expressed in the same neurons in the
hippocampus (Kokaia et al., 1993). BDNF/TrkB signaling facilitates long-term
potentiation (LTP), a form of long-lasting plasticity observed at synapses in the
hippocampus and other brain areas, and the proposed cellular mechanism of
memory formation (Korte et al., 1998). In the hippocampus, binding of BDNF to
the TrkB receptor leads to phosphorylation of NMDA receptors, which increases
NMDA-mediated Ca2+ influx (Levine et al., 1998; Crozier et al., 1999). The
intracellular Ca2+ elevation activates several calcium/calmodulin-dependent
kinases (Finkbeiner and Greenberg 1997). The TrkB receptor also activates
several MAP kinases. Activation of both cascades leads to enhanced gene
transcription (Finkbeiner and Greenberg 1997; Ying et al. 2002). Hippocampal
slices from BDNF heterozygous (BDNF+/–) mice fail to exhibit LTP (Korte et al.
1998). Application of mBDNF is sufficient to rescue LTP when protein synthesis
is inhibited, which suggests that mBDNF is a key protein synthesis product for
LTP expression (Pang et al. 2004). Thus, a model of hippocampal synaptic
plasticity has emerged whereby BDNF plays an important role in LTP induction.
Studies suggest that BDNF is also a critical element in photic phase-resetting
in the SCN. BDNF and TrkB are co-localized in the SCN. BDNF is rhythmically
expressed in the SCN, with high levels at night and low levels in the day (Liang et
al., 1998). SCN infusion of the TrkB receptor inhibitor K252a blocks or strongly
inhibits both the phase-delaying and phase-advancing effects of light during the
subjective night day (Liang et al., 1998). Heterozygous BDNF mutant mice
display a damped amplitude of light-induced phase shifts during the subjective
7

night. Conversely, infusion of exogenous BDNF into the SCN allows light pulses
to induce large phase advances during the middle of the subjective day, when
the circadian pacemaker is normally insensitive to photic perturbation. In vitro
experiments have shown that in the SCN, in order for glutamate to phase-shift
the clock, BDNF must concurrently activate its TrkB receptors (Liang et al., 1998;
Liang et al., 2000). BDNF could produce phase shifts through an increase in
intracellular calcium mediated by NMDA currents.
Another molecule that can affect glutamate signaling is neural cell adhesion
molecule (NCAM). NCAM is a homophilic glycoprotein located on the membrane
of neurons, glia and skeletal muscle (Hoffman et al. 1982; Edelman 1986).
NCAM has been implicated in processes such as cell-cell adhesion, neurite
outgrowth, synaptic plasticity and learning and memory (Bonfanti 2006). The
extracellular domain of NCAM consists of five immunoglobulin-like (Ig) domains
with different roles in homophilic binding (Kasper et al. 2000). For example,
polysialic acid (PSA) binds to the fifth Ig domain of NCAM, thereby reducing its
homophilic binding and cell adhesion properties, which are important in cell
migration (Ono et al. 1994; Hu, 2000). PSA-NCAM is found in discrete locations
of the adult brain, including the hippocampus, supraoptic nucleus (SON) and
SCN. In each of these areas, PSA-NCAM is also thought to play an important
role in neuronal plasticity. For example, in hippocampal slices, genetic removal of
NCAM leads to a deficit in LTP, which can be rescued by the BDNF application
(Muller et al., 2000). These data suggest a link between PSA-NCAM and BDNF
in the hippocampus.
8

In the SON, the PSA is considered an essential factor for morphological
plasticity. Lactation and dehydration normally induce withdrawal of astrocytic
processes around SON neurons, thereby increasing synaptic contacts in the
SON. Specific enzymatic removal of PSA from NCAM by microinjection of
endoneuraminidase (endo N) in the SON inhibits these structural changes and
prevents hormone secretion (Theodosis et al., 1999).
In the SCN, PSA content in the SCN fluctuates with high levels during the
day and low levels at night (Glass et al., 2003). Rhythmic fluctuations of PSA
content have also been shown in vitro (Prosser et al. 2003). Genetic deletion of
PSA affects circadian rhythm stability (Shen et al., 1997, 2001). Exposure to a
30-min light pulse during the late night dramatically increases the contents of
PSA in the SCN within 1 h (Glass et al., 2003). Likewise, in vitro glutamate
treatment rapidly increases PSA expression in the SCN (Prosser et al., 2003).
Together, these data suggest that the expression of PSA in the SCN is controlled
by both the circadian clock and photic input to the clock.
As in the hippocampus, evidence suggests a link between BDNF and PSANCAM in the SCN. BDNF actions in the SCN appear to require the PSA form of
NCAM. When PSA is removed by endo N, BDNF fails to activate its TrkB
receptor. Under these conditions, glutamate-induced phase shifts are blocked in
vitro (Prosser et al., 2003). One hypothesis regarding how PSA-NCAM and
BDNF interact is that the electronegatively-charged PSA may stabilize
electropositive BDNF and enhance its ability to bind its TrkB receptor (Kiss et al.,
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2001) The potential interactions between PSA-NCAM and BDNF, and their
participation in photic phase-resetting are illustrated in Fig. 1.

Activation of BDNF by Fibrinolytic Proteins

Tissue-type plasminogen activator (tPA) was originally identified in plasma as a
secreted serine protease that converts plasminogen to form plasmin, which is
involved in fibrinolysis. Fibrinolysis is the process where a fibrin clot, the product
of coagulation, is broken down. Plasmin cleaves fibrin, leading to the production
of circulating fragments that are cleared by other proteases (Sappino et al.,
1993). Increased tPA activity causes hyperfibrinolysis, or excessive bleeding,
whereas decreased activity causes hypofibrinolysis, or the increased blood clots.
In the plasma, tPA activity is inhibited by the protease inhibitor, plasminogen
activator inhibitor 1 (PAI-1) (Huntington and Carrell 2001). PAI-1 is the principal
inhibitor of both tPA and urokinase-type plasminogen activator (uPA), and hence
is an inhibitor of fibrinolysis. It is a member of the serine protease inhibitor
(serpin) superfamily. PAI-1 is maintained in an active state by interacting with the
protein, vitronectin (VN) (Mayasundari et al., 2004). VN is a 70kD glycoprotein
found in blood plasma and the extracellular matrix (ECM) (Preissner 1991;
Loskutoff et al. 1999). This protein consists of three domains: The N-terminal
domain, a central domain and a C-terminal domain. VN initially was crystallized
in complex with PAI-1 (Zhou et al., 2003). The N-terminal domain of VN binds
10

Figure 1. Model of cellular photic phase resetting in the SCN. Light causes the
release of glutamate (Glu) from retinal ganglion cells that project to the SCN via
the retinohypothalamic tract (RHT). Through the mechanisms shown here,
glutamate alters the transcription of circadian clock genes and shifts the circadian
clock to an earlier or later phase. Phase-shifting by glutamate requires the
neurotrophin brain-derived neurotrophic factor (BDNF) activating its receptor
(TrkB). PSA-NCAM stabilizes BDNF and enhances its ability to bind its TrkB
receptor.
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PAI-1 and stabilizes it, hence VN serves to regulate tPA-initiated proteolysis
(Dupont et al., 2009).
Another tPA inhibitor, neuroserpin, is found selectively in the brain (Hastings
et al., 1997; Krueger et al., 1997), suggesting that in addition to modulating
fibrinolysis in plasma, tPA performs other roles specifically within the nervous
system.
The function of tPA is not limited to fibrinolysis. More recently, tPA and its
associated proteins have been found to participate in a number of non-fibrinolysis
associated processes within the nervous system. tPA and its substrate,
plasminogen, are expressed in brain areas such as cortex, hippocampus and
cerebellum (Basham and Seeds 2001). For example, in the hippocampus, tPA
was identified as an immediate-early gene induced shortly after LTP (Qian et al.
1993). Research on the hippocampus has demonstrated that the tPA-plasmin
cascade converts proBDNF to mBDNF (Fig 2), which is then capable of
activating its TrkB receptor and enhancing NMDA receptor-mediated signaling
(Nicole et al., 2001; Pang et al., 2004). The application of mBDNF to
hippocampal slices can rescue impaired L-LTP in both tPA-deficient and
plasminogen-deficient mice.
tPA enhancement of NMDA receptor signaling can also be plasminindependent. It was reported in a neuronal cell culture system that tPA cleaves
the NR1 subunit at amino acid Arg260, leading to enhanced NMDA receptor
signaling (Nicole et al., 2001). Mutation of Arg260 abolished tPA-induced NMDA
activity (Fernandez-Monreal et al., 2004). An interaction between tPA and the
12

NR2B subunit of NMDA has been reported during ethanol withdrawal-induced
seizures, which are characterized by enhanced glutamatergic signaling (Pawlak
et al. 2005).
In addition to its physiological functions, an understanding of the role of tPA
in pathological situations has also expanded. For example, the tPA-plasmin axis
has been identified as participating in neuronal degeneration. Injecting the
excitotoxic glutamate analog, kainate, into the CA1 region of the hippocampus of
wild-type mice leads to neuronal damage, and this damage is reduced in either
tPA-deficient or plasminogen deficient mice (Tsirka et al. 1995, Gualandris et al.,
1996). Coinjection of α2-antiplasmin, an endogenous plasmin inhibitor, with
kainate, also prevents neurodegeneration, supporting the involvement of plasmin
in this pathological condition. Further investigation identified laminin, a
component of the ECM, as a substrate of plasmin proteolysis. Laminin cleavage
combined with kainate excitotoxicity results in neuronal degeneration (Tsirka et
al. 1997; Chen et al. 2003). tPA is also involved in other CNS pathologies. For
example, the tPA-plasmin system has been implicated in the degradation of βamyloid in Alzheimer disease in both mice and humans (Ledesma et al. 2000;
Melchor et al. 2003). Diminished tPA-plasmin activity could therefore contribute
to increased β-amyloid concentration, which in turn, leads to elevation of PAI-1
(Tucker et al. 2000; Melchor et al. 2003).
Although first found in the plasma and peripheral organs, respectively, PAI-1
and VN mRNA are also found in the CNS. PAI-1 mRNA is expressed in the
cerebral cortex after stoke, and VN mRNA is found in the meninges of the cortex
13

and spinal cord, and in close proximity to brain capillaries during mouse
development (Seiffert et al., 1995; Ahn et al., 1999). The functions of PAI-1 and
VN protein in the brain, however, are still largely unexplored.

Recent microarray studies have found that tPA, PAI-1, VN, and plasminogen
mRNA are also expressed in the SCN (Menger et al., 2005). tPA mRNA
expression is rhythmic in SCN, with high expression during the late day. PAI-1
mRNA is also rhythmically expressed, with its highest levels during the early
night (Menger et al., 2005). mRNA for plasminogen and VN do not show rhythmic
expression in the SCN (Menger et al., 2005). Because of the strong parallels
already shown between LTP-associated processes in the hippocampus and
photic phase-shifting processes in the SCN, we hypothesized that the tPA
proteolytic pathway may function in the SCN to activate BDNF, thereby
enhancing glutamate signaling (Fig. 2). Based on this hypothesis, we sought to
answer a number of key questions: First, is tPA involved in glutamate actions in
the SCN? If so, is the ability of tPA to modulate glutamate signaling in the SCN
constant throughout the day and night? Second, do the actions of tPA involve
plasmin-dependent processes? Third, do VN and PAI-1 inhibit tPA activity in the
SCN? Fourth, what are the temporal expression patterns of tPA, plasmin and
BDNF in SCN? Does glutamate modulate their expression? The first three
questions are addressed in chapter 2, question 4 is addressed in chapter 3.
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Figure 2. In the hippocampus, tissue-type plasminogen activator (tPA) activates
BDNF through converting plasminogen to plasmin, which converts proBDNF to
mature BDNF, which is required for long-term potentiation (LTP). In the plasma,
tPA is inhibited by plasminogen activator inhibitor-1 (PAI-1), while vitronectin
binds to and enhances PAI-1 activity.
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CHAPTER II
Tissue-type Plasminogen Activator-Plasmin-BDNF Modulate
Glutamate-induced Phase-shifts of the Mouse Suprachiasmatic
Circadian Clock in vitro
(Published in European Journal of Neuroscience, Vol.30, pp.1451-1460, 2009)

Abstract
The mammalian circadian clock in the suprachiasmatic nucleus (SCN) maintains
environmental synchrony through light signals transmitted by glutamate released
from retinal ganglion terminals. Brain-derived neurotrophic factor (BDNF) is
required for light/glutamate to reset the clock. In the hippocampus, BDNF is
activated by the extracellular protease, plasmin, which is produced from
plasminogen by tissue-type plasminogen activator (tPA). We provide data
showing expression of proteins from the plasminogen activation cascade in the
SCN and their involvement in circadian clock phase-resetting. Early night
glutamate application to SCN containing brain slices resets the circadian clock.
Plasminogen activator inhibitor-1 (PAI-1) blocked these shifts in slices from
wildtype mice but not mice lacking its stabilizing protein, vitronectin (VN).
Plasmin, but not plasminogen, prevented inhibition by PAI-1. Both plasmin and
active BDNF reversed 2-antiplasmin inhibition of glutamate-induced shifts. 2Antiplasmin decreased the conversion of inactive to active BDNF in the SCN.
Finally, both tPA and BDNF allowed daytime glutamate-induced phase-resetting.
Together, these data are the first to demonstrate expression of these proteases
in the SCN, their involvement in modulating photic phase-shifts, and their
activation of BDNF in the SCN, a potential ‘gating’ mechanism for photic phase16

resetting. These data also demonstrate a functional interaction between PAI-1
and VN in adult brain. Given the usual association of these proteins with the
extracellular matrix, these data suggest new lines of investigation into the
locations and processes modulating mammalian circadian clock phase-resetting.

Introduction
The mammalian circadian oscillator located in the suprachiasmatic nucleus (SCN)
regulates daily behavioral and physiological rhythms (Moore & Eichler, 1972;
Stephan & Zucker, 1972). The SCN clock synchronizes with the environment
primarily through light signals received by the retina. Light phase-shifts the clock
during the night through cellular mechanisms not fully understood. Retinal
stimulation causes glutamate release within the SCN, which activates N-methyldaspartate (NMDA) receptors, leading to postsynaptic Ca2+ influx and activation
of nitric oxide synthase (Ding et al., 1994). Downstream activation of protein
kinases and transcriptional regulators leads to altered transcription of clockassociated genes and resetting of core clock mechanisms (Ding et al., 1997;
Gillette & Tischkau, 1999; Butcher et al., 2003, 2004, 2005; Pizzio et al., 2003;
Marpegan et al., 2004; Cheng et al., 2006). Brain-derived neurotrophic factor
(BDNF) and its receptor, TrkB, are also necessary for photic phase-shifts. BDNF
protein levels fluctuate rhythmically in the SCN with high levels at night, when
light and glutamate can phase-shift the clock (Liang et al., 1998). Blocking TrkB
receptors inhibits light- and glutamate-induced phase-shifts (Liang et al., 2000;
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Michel et al., 2006). Also, light-induced phase shifts are substantially attenuated
in BDNF+/- mice (Liang et al., 2000). Finally, exogenous BDNF administration
during the subjective day allows light and glutamate to induce phase-shifts in the
daytime in vivo and in vitro, respectively (Liang et al., 2000; Michel et al., 2006).
These data raise the possibility that BDNF serves to gate photic phaseshifts.
BDNF and TrkB are also expressed in the hippocampus (Kokaia et al., 1993). In
the hippocampus, BDNF is synthesized as a precursor, proBDNF, which is
converted to its mature form (mBDNF) through the tissue-type plasminogen
activator (tPA)/plasmin system. tPA is an extracellular serine protease that is
expressed and secreted in the hippocampus in response to glutamate stimulation
(Shin et al., 2004), and has been implicated in the modulation of synaptic
plasticity (Horwood et al., 2001; Pang et al., 2004). The specific downstream
target of tPA proteolysis is the zymogen plasminogen. tPA converts plasminogen
to its active form, plasmin, through proteolytic cleavage (Plow et al., 1995).
Plasmin then cleaves proBDNF to form mBDNF (Lee et al., 2001). Plasminogen-/mice exhibit severely impaired long-term potentiation (LTP) in the hippocampus.
Application of mBDNF but not proBDNF completely rescues LTP

in

plasminogen-/- mice (Pang et al., 2004).
In plasma, tPA cleavage of plasminogen is countered by the serine protease
inhibitor (serpin), plasminogen activator inhibitor-1 (PAI-1; Huntington & Carrell,
2001). PAI-1 is maintained in its active state by binding with vitronectin (VN;
Podor et al., 2000a, b; Minor & Peterson, 2002; Mayasundari et al., 2004).
Functional interactions between PAI-1 and VN in the adult brain have not been
18

investigated. Microarray studies have found that VN, PAI-1, tPA and
plasminogen mRNA are expressed in the SCN (Panda et al., 2002; Menger et al.,
2005), with tPA and PAI-1 mRNA showing rhythmic expression (Panda et al.,
2002; Menger et al., 2005). Based on these data, we investigated whether tPA
and plasmin modulate glutamate-induced phase-shifts in the SCN in a PAI-1/VNdependent fashion.

Materials and methods
Brain slice preparation
Coronal brain slices (500u) containing the SCN were prepared during the early
subjective day from adult male (> 8 weeks old) C57Bl/J6 (Harlan Laboratories)
and VN knockout (VN-/-) mice housed in a 12: 12 h light: dark cycle (VN-/- mice
were generated from C57Bl/J6 mice and kindly provided by Dr Ginsburg at the
University of Michigan). Mice were killed by decapitation. The slices were
maintained at the interface of a Hatton-style brain slice chamber continuously
perfused at 37°C with oxygenated (95% O2/ 5% CO2) Earle’s balanced salt
solution supplemented with glucose, bicarbonate and gentamicin. The pH was
adjusted to 7.4 (Prosser, 2003). One mouse was used for each experiment, with
replicate experiments performed on brain slices from different mice. All
experimental protocols were approved by the University of Tennessee Knoxville
Institutional Animal Care and Use Committee.

19

Drug treatments
All treatments were bath-applied on the first day in vitro. To apply the treatments,
perfusion of the normal medium was stopped and the medium in the chamber
was replaced with medium containing the appropriate compounds. Glutamate
application was for 10 min, beginning at Zeitgeber time 16 (ZT16, where ZT0
corresponds to lights on and ZT12 corresponds to lights off in the donor animal
colony). In experiments involving compounds other than glutamate, the slices
were pre-treated with the other substances alone for 30 min (ZT15.5-16.0), and
then were co-treated with glutamate for 10 min (ZT16.0-16.17). In additional
experiments, the compounds other than glutamate were applied alone for 40 min
(ZT15.5-16.17). At the end of the treatments, the normal medium was
reintroduced into the slice chamber and perfusion was resumed.
Single-unit recording and data analysis
Single-unit recordings were obtained on day 2 in vitro using methods described
previously (Prosser, 1998, 2003). Briefly, spontaneous activity of single SCN
neurons was recorded extracellularly using glass capillary microelectrodes filled
with 3 M NaCl. Individual neurons were recorded for 5 min, with four-seven cells
being recorded each hour. The data were later analysed using a DataWave
system (Berthoud, CO, USA) to determine the average firing rates. The individual
firing rates were then used to calculate 2-h running averages, lagged by 1 h, to
obtain a measure of population neuronal activity. The time of peak neuronal
activity was assessed visually by estimating, to the nearest quarter hour, the time
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of symmetrically highest activity. As is the accepted standard for these types of
experiments (Prosser et al., 1994; Ding et al., 1997, 1998; Prosser, 2003; Soscia
& Harrington, 2004; Tischkau et al., 2004; Yannielli & Harrington, 2004), phaseshifts were calculated as the difference in time-of-peak between untreated
(control) slices and drug-treated slices. Statistical analyses were performed using
Sigmastat (San Jose, CA, USA). One-way anova was used to test for significant
differences between treatment and control experiments, followed by Dunnett’s
test for post hoc comparisons. Significance was set at p < 0.05.

Western blots
To assess in vivo protein expression, SCN tissue was dissected from mouse
brains and immediately frozen for later Western blot assay. In all other protein
assay experiments brain slices containing the SCN and underlying optic chiasm
were prepared and maintained undisturbed in the slice chamber for harvesting
later. At the appropriate time, the tissue was then removed and homogenized in
ice-chilled HEPES-based extraction buffer containing a protease inhibitor cocktail
(1 mm phenylmethylsulfonyl fluoride, 10 mg/mL aprotinin, 15 mg/mL leupeptin,
10 mg/mL pepstatin). For the BDNF immunoblot, tissue was prepared in Trisbased denaturing extraction buffer [4 M urea, 0.02 M dithiothreitol, 0.05 M Tris,
pH 7.4, 2% sodium dodecyl sulfate (SDS)]. The tissue extract sample was
separated into aliquots and stored at -80°C. Protein content of the extract was
determined by the bicinchoninic acid method (BCA; Pierce). Tissue samples
were mixed with loading buffer (pH 6.8 Tris, SDS, bromophenol blue, glycerol),
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and subjected to SDS–polyacrylamide gel electrophoresis (PAGE). Proteins were
electrotransferred onto nitrocellulose membranes, which were then incubated
with blocking buffer [10% solution of non-fat dry milk in phosphate-buffered saline
with Tris (PBST)]. The membranes were probed with primary antibodies diluted
in a 2.0% solution of non-fat dry milk in PBST, followed by goat anti-rabbit
horseradish peroxidase-conjugated secondary antibody at appropriate dilutions
in

the

same

buffer.

Signals

were

revealed

by

enzyme-catalysed

chemiluminescence (Pierce, IL, USA). The amount of protein loaded in each lane
was assessed by probing for actin, so all protein expression is reported as levels
relative to actin. Control experiments included running parallel lanes loaded with
the corresponding native proteins (positive controls), and probing membranes
with primary antibodies pre-incubated with the native protein to test for crossreactivity and to establish the specificity of the antibody samples. Rabbit antiplasminogen, anti-tPA, anti-PAI-1 and anti-VN antibodies were obtained from
Molecular Innovations (Detroit, MI, USA), and rabbit anti-actin and anti-BDNF
antibodies were from Santa Cruz Biochemicals (Santa Cruz, CA, USA).

Results
Expression of fibrinolytic proteins and BDNF in the SCN
Although microarray studies have shown gene expression for tPA, VN, PAI-1 and
plasminogen in the SCN (Panda et al., 2002; Menger et al., 2005), no studies
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have focused on expression of the respective proteins. Therefore, in these
experiments we used Western blot procedures to assess which of these proteins
are expressed in the SCN at ZT16, when light/glutamate can reset the SCN clock.
For these experiments we prepared slices that were smaller than those used in
the electrophysiology experiments, so that they contained only the SCN and
underlying optic chiasm. Individual slices were maintained in the slice chamber
until ZT16, when they were removed and subjected to homogenization and
protein quantification.
As shown in Fig. 3A, anti-PAI-1 antibody identified an approximately 45-kD
band in SCN samples from wild-type brain slices. Immunoreactive bands of VN
and PAI-1 were slightly larger than their positive controls, presumably due to
glycosylation (Uchibori-Iwaki et al., 2000; Brogren et al., 2008). We detected tPA
protein in SCN samples from both VN-/- knockout (data not shown) and wild-type
mice as an approximately 60-kD band that matched the positive control. As
documented previously (Zheng et al., 1995), we found no VN protein in SCN
tissue from VN-/- mice (data not shown). We identified plasminogen as an
approximately 90-kD band that matched the positive control, whereas plasmin
was seen as approximately 50-kD and approximately 40-kD bands under
reducing conditions. Mature BDNF protein was consistently detected by Western
blot analysis of pooled samples of three SCN slices as a prominent
immunoreactive band with a molecular size of 15 kD (Fig. 3B). We also observed
bands of approximately 25 kD and approximately 37 kD, which correspond to
proBDNF (Mowla et al., 2001; Pollak et al., 2005). To verify antibody specificity,
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anti-BDNF, anti-PAI-1, anti-tPA and anti-plasminogen primary antibodies were
incubated with and without corresponding purified proteins in solution to test for
specific competition in the Western blot.
In a second set of experiments, SCN tissue was placed in extraction buffer for
Western blot analysis immediately after dissection in order to assess in vivo
protein expression. The results (Fig. 3C) demonstrated that the fibrinolytic
proteins (tPA, PAI-1, plasminogen, VN) are all expressed in the SCN in vivo.
In a final set of experiments assaying protein expression, we prepared SCN
brain slices and maintained them in vitro for 3, 6 and 9 h prior to placing them in
extraction buffer. Western blot analysis for tPA protein in these slices
demonstrated no pronounced trauma-induced changes in the expression of tPA
protein (Fig. 3D). Glutamate-induced phase delays are blocked by PAI-1.
SCN neuronal activity recorded on day 2 in vitro exhibited a circadian rhythm
with a peak during mid-day (Fig. 4). The mean (± SEM) time of peak neuronal
activity in control experiments (untreated slices) was ZT6.06±0.22 (n = 4). These
results are consistent with previous work (Prosser, 2003). Glutamate (1 mM)
applied to brain slices in the early subjective night for 10 min (ZT16-16.17)
delayed the SCN neuronal activity rhythm (Fig. 4), so that the mean time-of-peak
occurred at ZT8.75 ± 0.47 (n = 3). Thus, the mean phase-shift was -2.69 h.
These data are consistent with previous studies (Ding et al., 1994; Prosser et al.,
2003). Pre-treating brain slices for 30 min prior to glutamate treatment with the
tPA inhibitor, PAI-1, blocked the glutamate-induced phase-shifts (mean phaseshift =-0.38 ± 0.4 h, n = 4; Figs 4 and 5). PAI-1 inhibition was dose-dependent,
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with an ED50 (dosage of drug that produces 50% of the maximum effect) of about
0.6 nM (Fig. 5). This corresponds to its concentration in the serum (Devy et al.,
2002). From this value, it is clear that tissue injury in our SCN slice preparation
procedure did not induce a sustained release of tPA. The inhibition by PAI-1 was
prevented by coapplication of excess tPA (1 ug/mL) with the PAI-1, so that the
resulting phase-shift was -2.69 ± 0.18 h (n = 3; Figs 4 and 5). When applied
alone, PAI-1 and tPA each had no effect on the phase of the neuronal activity
rhythm. The effects of all these treatments are summarized in Fig. 5.
Glutamate-induced phase delays are blocked by PAI-1
SCN neuronal activity recorded on day 2 in vitro exhibited a circadian rhythm with
a peak during mid-day (Fig. 4). The mean (± SEM) time of peak neuronal activity
in control experiments (untreated slices) was ZT6.06±0.22 (n = 4). These results
are consistent with previous work (Prosser, 2003). Glutamate (1 mM) applied to
brain slices in the early subjective night for 10 min (ZT16-16.17) delayed the
SCN neuronal activity rhythm (Fig. 4), so that the mean time-of-peak occurred at
ZT8.75 ± 0.47 (n = 3). Thus, the mean phase-shift was -2.69 h. These data are
consistent with previous studies (Ding et al., 1994; Prosser et al., 2003). Pretreating brain slices for 30 min prior to glutamate treatment with the tPA inhibitor,
PAI-1, blocked the glutamate-induced phase-shifts (mean phase-shift =-0.38 ±
0.4 h, n = 4; Figs 4 and 5). PAI-1 inhibition was dose-dependent, with an ED50
(dosage of drug that produces 50% of the maximum effect) of about 0.6 nM (Fig.
5). This corresponds to its concentration in the serum (Devy et al., 2002). From
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this value, it is clear that tissue injury in our SCN slice preparation procedure did
not induce a sustained release of tPA. The inhibition by PAI-1 was prevented by
coapplication of excess tPA (1 ug/mL) with the PAI-1, so that the resulting phaseshift was -2.69 ± 0.18 h (n = 3; Figs 4 and 5). When applied alone, PAI-1 and tPA
each had no effect on the phase of the neuronal activity rhythm. The effects of all
these treatments are summarized in Fig. 5.
Glutamate-induced phase delays are blocked by PAI-1
SCN neuronal activity recorded on day 2 in vitro exhibited a circadian rhythm with
a peak during mid-day (Fig. 4). The mean (± SEM) time of peak neuronal activity
in control experiments (untreated slices) was ZT6.06±0.22 (n = 4). These results
are consistent with previous work (Prosser, 2003). Glutamate (1 mM) applied to
brain slices in the early subjective night for 10 min (ZT16-16.17) delayed the
SCN neuronal activity rhythm (Fig. 4), so that the mean time-of-peak occurred at
ZT8.75 ± 0.47 (n = 3). Thus, the mean phase-shift was -2.69 h. These data are
consistent with previous studies (Ding et al., 1994; Prosser et al., 2003). Pretreating brain slices for 30 min prior to glutamate treatment with the tPA inhibitor,
PAI-1, blocked the glutamate-induced phase-shifts (mean phase-shift =-0.38 ±
0.4 h, n = 4; Figs 4 and 5). PAI-1 inhibition was dose-dependent, with an ED50
(dosage of drug that produces 50% of the maximum effect) of about 0.6 nM (Fig.
5). This corresponds to its concentration in the serum (Devy et al., 2002). From
this value, it is clear that tissue injury in our SCN slice preparation procedure did
not induce a sustained release of tPA. The inhibition by PAI-1 was prevented by
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coapplication of excess tPA (1 ug/mL) with the PAI-1, so that the resulting phaseshift was -2.69 ± 0.18 h (n = 3; Figs 4 and 5). When applied alone, PAI-1 and tPA
each had no effect on the phase of the neuronal activity rhythm. The effects of all
these treatments are summarized in Fig. 5.
Glutamate-induced phase delays are blocked by PAI-1
SCN neuronal activity recorded on day 2 in vitro exhibited a circadian rhythm with
a peak during mid-day (Fig. 4). The mean (± SEM) time of peak neuronal activity
in control experiments (untreated slices) was ZT6.06±0.22 (n = 4). These results
are consistent with previous work (Prosser, 2003). Glutamate (1 mM) applied to
brain slices in the early subjective night for 10 min (ZT16-16.17) delayed the
SCN neuronal activity rhythm (Fig. 4), so that the mean time-of-peak occurred at
ZT8.75 ± 0.47 (n = 3). Thus, the mean phase-shift was -2.69 h. These data are
consistent with previous studies (Ding et al., 1994; Prosser et al., 2003). Pretreating brain slices for 30 min prior to glutamate treatment with the tPA inhibitor,
PAI-1, blocked the glutamate-induced phase-shifts (mean phase-shift =-0.38 ±
0.4 h, n = 4; Figs 4 and 5). PAI-1 inhibition was dose-dependent, with an ED50
(dosage of drug that produces 50% of the maximum effect) of about 0.6 nM (Fig.
5). This corresponds to its concentration in the serum (Devy et al., 2002). From
this value, it is clear that tissue injury in our SCN slice preparation procedure did
not induce a sustained release of tPA. The inhibition by PAI-1 was prevented by
coapplication of excess tPA (1 ug/mL) with the PAI-1, so that the resulting phaseshift was -2.69 ± 0.18 h (n = 3; Figs 4 and 5). When applied alone, PAI-1 and tPA
27

Figure 3. Expression of vitronectin (VN), plasminogen activator inhibitor-1 (PAI1), plasminogen, plasmin, tissue-type plasminogen activator (tPA) and brainderived neurotrophic factor (BDNF) in the SCN. (A–C) Samples maintained in
vitro for 12–14 h, until ZT16. (A) Lane 1 shows native protein controls; lane 2
shows SCN protein samples. (B) Lane 1 shows BDNF protein control; lanes 2
and 3 shows SCN protein samples, with lane 3 a longer-duration exposure of the
same blot shown in lane 2. (C) Lane 1 shows native protein controls; lane 2
shows SCN protein samples placed in extraction buffer immediately after
dissection. Westerns shown here were run under non-reducing conditions, so
plasmin bands do not separate from plasminogen. (D) Histogram showing tPA
levels (relative to actin) at different times after slice preparation (n = 3 for each
time point). Data are normalized to samples obtained after 9 h in vitro.
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each had no effect on the phase of the neuronal activity rhythm. The effects of all
these treatments are summarized in Fig. 5.
Plasmin activation of BDNF is necessary for glutamate-induced phase
delays
Next we investigated whether the actions of tPA in the SCN result directly from
the conversion of plasminogen to plasmin. If the effects are specific and require
the plasminogen activation cascade to produce plasmin, then co-application of
active plasmin should overcome the effect of blocking tPA activity. Therefore, in
the next set of experiments, we co-applied either plasmin (40 ug/mL) or
plasminogen (40 ug/mL) with PAI-1 beginning 30 min prior to glutamate
administration. Glutamate-induced phase-shifts were restored by plasmin (mean
shift = -3.69 ± 0.47 h, n = 3), whereas co-application of plasminogen did not
prevent PAI-1 inhibition (mean phaseshift = -0.04 ± 0.29 h, n = 5; Fig. 6).
Plasminogen and plasmin alone had no effect.
To further examine the requirement for plasmin in glutamate phaseshifts, we
co-applied the endogenous plasmin antagonist, 2-antiplasmin, along with
glutamate at ZT16. Consistent with the previous results, 2-antiplasmin also
inhibited glutamate-induced phase-shifts (Fig. 6). This inhibition was dosedependent (Fig. 6), with an ED50 estimated at 10 nM. Finally, the inhibition by 2antiplasmin was prevented by co-application of excess plasmin (80 ug/mL; mean
phase-shift = -2.19 ± 0.47 h, n = 3; Fig. 6). In control experiments, 2-antiplasmin
had no effect on the phase of the neuronal activity rhythm (Fig. 6).
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Figure 4. Glutamate-induced phase-shifts of neuronal activity are blocked by
plasminogen activator inhibitor-1 (PAI-1). Shown here are the 2-h means ± SEM
of spontaneous neuronal activity recorded in single experiments. (A) Control
experiment shows peak activity at ZT6. (B) Glutamate (1 mm) treatment at ZT16
induces a nearly 3-h phase delay. (C) PAI-1 (0.5 um) treatment beginning at
ZT15.5 blocks the glutamate-induced phase-shift. (D) Co-application of tissuetype plasminogen activator (tPA; 1 ug/mL) with PAI-1 prevents the PAI-1
inhibition. Vertical bars show the time of drug treatment. The dotted line shows
the mean time-of-peak in control experiments. Horizontal black bars represent
lights-off in the animal colony.

30

Figure 5. Modulation of glutamate-induced phase-shifts by tissue-type
plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1). PAI-1
blocks glutamate-induced phase delays in a dose-dependent fashion. (A) Shown
are the mean (± SEM) phase-shifts induced by the treatments indicated. PAI-1 (5
nm) blocks glutamate-induced phase delays, while excess tPA (1 ug/mL)
prevents this inhibition. In control experiments, PAI-1 and tPA applied alone or
together had no effect on the phase of neuronal activity. One-way ANOVA
indicated a significant effect of the treatments (F6,18=14.13). *Phase delays
significantly different from control (no treatment) slices based on post hoc
(Dunnett’s) test (p<0.001). (B) Mean (± SEM) phase-shifts induced by glutamate
applied with varying concentrations of PAI-1. Delays are plotted as negative
values. ZT, Zeitgeber time.
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Plasmin activation of BDNF is necessary for glutamate-induced phase
delays
Next we investigated whether the actions of tPA in the SCN result directly from
the conversion of plasminogen to plasmin. If the effects are specific and require
the plasminogen activation cascade to produce plasmin, then co-application of
active plasmin should overcome the effect of blocking tPA activity. Therefore, in
the next set of experiments, we co-applied either plasmin (40 ug/mL) or
plasminogen (40 ug/mL) with PAI-1 beginning 30 min prior to glutamate
administration. Glutamate-induced phase-shifts were restored by plasmin (mean
shift = -3.69 ± 0.47 h, n = 3), whereas co-application of plasminogen did not
prevent PAI-1 inhibition (mean phaseshift = -0.04 ± 0.29 h, n = 5; Fig. 6).
Plasminogen and plasmin alone had no effect.
To further examine the requirement for plasmin in glutamate phaseshifts, we
co-applied the endogenous plasmin antagonist, 2-antiplasmin, along with
glutamate at ZT16. Consistent with the previous results, 2-antiplasmin also
inhibited glutamate-induced phase-shifts (Fig. 6). This inhibition was dosedependent (Fig. 6), with an ED50 estimated at 10 nM. Finally, the inhibition by 2antiplasmin was prevented by co-application of excess plasmin (80 ug/mL; mean
phase-shift = -2.19 ± 0.47 h, n = 3; Fig. 6). In control experiments, 2-antiplasmin
had no effect on the phase of the neuronal activity rhythm (Fig. 6).
In the next set of experiments, we investigated whether plasmin functions in
the SCN to activate BDNF. For these experiments we applied exogenous
mBDNF (200 ng/mL), beginning 30 min prior to co-application of glutamate and
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2-antiplasmin. mBDNF pre-treatment fully restored the glutamate-induced
phase-shifts that were inhibited by 2-antiplasmin (mean phase-shift = -2.11 ±
0.41 h, n = 3; Fig. 6), while mBDNF treatment alone had no effect (mean phaseshift = 0.06 ± 0.00 h, n = 2; Fig. 6). These data support the conclusion that
plasmin acts in the SCN to convert proBDNF to mBDNF.
Finally, we investigated whether 2-antiplasmin treatment alters the production
of mBDNF in the SCN. SCN brain slices were left untreated, treated with
glutamate, or treated with glutamate + 2-antiplasmin for 10 min at ZT16. At the
end of this time slices were removed from the slice chamber and processed for
Western blot analysis. The results (Fig. 6) indicate that glutamate treatment did
not affect the level of mBDNF in the SCN, but glutamate + 2-antiplasmin
treatment significantly decreased the amount of mBDNF in the SCN. These data
are consistent with the hypothesis that plasmin functions in the SCN to activate
BDNF.
Involvement of tPA-plasmin-BDNF in late subjective night phase advances
The experiments described above were all conducted during the early
subjective night, investigating glutamate-induced phase delays. Because there
are significant differences in the phase-resetting mechanisms associated with
photic phase delays and phase advances, it is important to determine whether
these proteins also modulate glutamate-induced phase advances. Glutamate
application alone at ZT23 induced 3-h phase advances, as shown previously
(Ding et al., 1994; Prosser et al., 2003). As seen with early night drug treatments,
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Figure 6. Plasmin activity is necessary for glutamate-induced phase-shifts. (A)
Shown are the mean (± SEM) phase-shifts induced by the treatments indicated.
Exogenous plasmin (40 ug/mL), but not plasminogen (40 ug/mL), prevents
plasminogen activator inhibitor-1 (PAI-1) inhibition of glutamate-induced phaseshifts. The endogenous plasmin inhibitor, 2-antiplasmin (0.05 uM), inhibits
glutamate-induced phase-shifts, and this inhibition is reversed by either excess
plasmin (80 ug/mL) or (m)brain-derived neurotrophic factor (BDNF; 200 ng/mL).
In control experiments, plasmin (40 lg/mL), plasminogen, a2-antiplasmin and
mBDNF in isolation had no effects on the phase of neuronal activity. One-way
anova indicated a significant effect of the treatments (F10,37 = 20.4). *Phase
delays significantly different from control (no treatment) slices based on post hoc
(Dunnett’s) test (p<0.001). See Fig. 5 for details. (B) 2-Antiplasmin dosedependently blocks glutamate-induced phase delays. Shown are the mean (±
SEM) phase-shifts induced by glutamate applied with varying concentrations of
2-antiplasmin. Delays are plotted as negative values. (C) Glutamate treatment
did not alter mBDNF protein expression in the SCN, but glutamate + 2antiplasmin treatment significantly decreased the amount of mBDNF in the SCN
(p= 0.01). ZT, Zeitgeber time
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co-application of either PAI-1 or 2-antiplasmin blocked the glutamate-induced
phase advances. Furthermore, although BDNF treatment alone at ZT23 had no
effect, BDNF was able to prevent the inhibition induced by 2-antiplasmin (Fig. 7).

BDNF acts as a gating molecule for photic phase-resetting
The data thus far indicate that mBDNF is important for glutamate-induced phaseresetting. These data are consistent with previous studies showing that BDNF
protein levels are high in the SCN during the night, when light phase-shifts the
clock (Liang et al., 1998). Furthermore, blocking BDNF activity with K252a
prevents photic phase-resetting (Liang et al., 2000; Michel et al., 2006), while
continuous infusion of BDNF allows photic phase-shifts during the day (Liang et
al., 2000). To further explore the potential role of mBDNF as a gating molecule
for photic phase-resetting, we initiated a series of experiments investigating the
effects of daytime BDNF signaling in the SCN.

Control slices that received treatments of either 10 min glutamate at ZT6 or 40
min mBDNF (100 ng/mL) starting at ZT5.5 did not show significant phaseresetting responses (-0.18 ± 0.0 h and -0.27 ± 0.4 h, respectively). However,
slices treated with glutamate+ BDNF underwent phase advances averaging 3.32
± 0.3 h. These daytime phase advances were blocked by co-treatment with the
TrkB antagonist, K252a (mean phase advance = 0.07 ± 0.2 h, n = 3). K252a
treatment alone during the subjective day had no effect (Fig. 8).
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Figure 7. tPA-plasmin-brain-derived neurotrophic factor (BDNF) modulation of
late-night phase advances by glutamate. Shown are the mean phase-shifts
induced by treatments applied to SCN brain slices at Zeitgeber time (ZT) 23.
Glutamate induced a 3-h phase advance, which was inhibited by either
plasminogen activator inhibitor-1 (PAI-1) or 2-antiplasmin treatment. Coapplication of BDNF prevented the inhibition by 2-antiplasmin, while it had no
effect when applied alone. One-way ANOVA indicated a significant effect of the
treatments (F5,17 = 53.19). *Phase-shifts significantly different from control (no
treatment) slices based on post hoc (Dunnett’s) test (p< 0.001).
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To investigate whether daytime BDNF availability is regulated by tPA, we also
investigated whether glutamate induces daytime phase advances when applied
together with tPA. As shown in Fig. 8, co-treatment of SCN brain slices with
glutamate + tPA at ZT6 also induced a phase advance. These data suggest that
the amount of active tPA in the SCN is limited in the daytime.

VN is necessary for PAI-1 actions in the SCN
Having shown that PAI-1 can block tPA activity in the SCN, we next
investigated whether VN is needed for sustained PAI-1 activity in the SCN. In the
plasma, VN acts as a cofactor, binding to PAI-1 and maintaining it in its active
form (Podor et al., 2000b; Minor & Peterson, 2002). If this protein interaction
occurs in the SCN, then PAI-1 inhibition of glutamate-induced phase-shifts
should be impaired in VN knockout (VN-/-) mice. Therefore, we investigated
glutamate-induced phase-shifts in brain slices prepared from VN-/- mice. First, we
conducted control experiments for VN-/- mice. In vitro SCN neuronal activity from
VN-/- mice exhibited a circadian rhythm with a peak during mid-day (mean time of
peak = ZT6.75 ± 0.30, n = 3; Fig. 9). This time-of-peak is not significantly
different from that observed in wild-type SCN brain slices. Although a detailed
assessment of photic entrainment in the VN-/- mice is beyond the scope of this
study, the fact that the phase of the SCN neuronal activity rhythm seen in vitro
matches that seen in brain slices from wild-type mice suggests there is no major
detriment in photic entrainment in these mice. This result would be expected in
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Figure 8. Brain-derived neurotrophic factor (BDNF) gates glutamate-induced
phase-shifts. Shown are the mean phase-shifts induced by treatments applied to
SCN brain slices during the subjective day. Glutamate and BDNF treatments
applied individually had no effect, while together they induced a 3-h phase
advance. The TrkB antagonist, K252a, prevented this phase-shift. Co-treatment
with glutamate and tissue-type plasminogen activator (tPA) also phase advanced
the neuronal activity rhythm. One-way ANOVA indicated a significant effect of the
treatments (F6,19 = 42.1). *Phase-shifts significantly different from control (no
treatment) slices based on post hoc (Dunnett’s) test (p< 0.001). ZT, Zeitgeber
time.
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the absence of VN, a cofactor and stabilizer of PAI-1, which appears to be an
inhibitor of entrainment processes. To maintain consistency in the analyses used
throughout this study, therefore, we continued to calculate phase-shifts relative to
the mean time-of-peak in the SCN from wild-type mice. Glutamate-induced
phase delays in VN-/- SCN brain slices were the same magnitude as those seen
in wild-type brain slices (mean phase shift= -2.44 ± 0.35 h, n = 2; Fig. 9). Next,
we applied PAI-1 and glutamate in the same manner as used in our previous
experiments. Unlike the results obtained using wild-type tissue, PAI-1 did not
block glutamate-induced phase-shifts in SCN brain slices prepared from VN-/mice (mean phase-shift = -2.63 ± 0.25 h, n = 4; Fig. 9).
To confirm that the tPA-plasminogen-plasmin pathway is functional in the SCN
of VN-/- mice, we co-applied 2-antiplasmin with glutamate to SCN brain slices
from VN-/- mice. As seen with wild-type tissue, 2-antiplasmin inhibited glutamateinduced phase-shifts (mean phase shift = -0.42 ± 0.10 h, n = 3; Fig. 9). In control
experiments on VN-/- SCN tissue, PAI-1 alone had no effect (mean phase shift = 0.67 ± 0.11 h, n = 3), while 2-antiplasmin induced a small phase advance (0.75
± 0.43 h, n = 3; Fig. 9).

Discussion
The results presented here are the first to demonstrate expression of tPA and its
associated proteins in the SCN, and to begin elucidating their functions
associated with the SCN circadian clock. We show that tPA-dependent
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generation of plasmin is necessary for glutamate-induced phase-shifts, and tPA
activity in the SCN is inhibited by PAI-1 paired with its cofactor, VN. These data
significantly expand the known functions of these proteins within the nervous
system, and demonstrate a novel and unexpected regulatory process modulating
photic-resetting of the mammalian circadian system.
Our initial experiments focused on tPA. A role for tPA in enhancing glutamate
signaling in the SCN is consistent with studies showing that tPA enhances
glutamatergic excitotoxicity that is associated with stroke-related brain injury
(Dietzmann et al., 2000; Yepes et al., 2002; Kumada et al., 2004). In the SCN,
however, tPA is involved as a component in a normal regulatory mechanism
rather than a pathological process. In this regard, tPA actions in the SCN are
similar to those in the hippocampus, where the protease modulates glutamatedependent memory processes in a normal physiological context (Pang et al.,
2004). Our data do not address the issue of whether urokinase plasminogen
activator (uPA) is involved in these processes. uPA is expressed in the brain,
although its expression in the adult brain appears to be more associated with
tumor growth than with normal processes (Zhang et al., 2005). Future
experiments using tPA and uPA knockout mice could explore the relative
importance of these two plasminogen activators in regulating plasmin levels in
the SCN.
PAI-1 is mainly produced by endothelial cells lining blood vessels, where it
decreases blood clot lysis by inhibiting tPA (Reilly &Hutzelmann, 1992; Fay et al.,
1994). Its expression and actions in the brain, however, are not well understood.
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Figure 9. Vitronectin (VN) is needed for plasminogen activator inhibitor-1 (PAI-1)
to block glutamate-induced phase-shifts. Shown are the mean phase-shifts
generated by application of the treatments indicated to SCN brain slices obtained
from VN-/- mice (calculated relative to the time-of-peak in wild-type SCN controls).
The time of peak neuronal activity in VN-/- SCN brain slices is not significantly
different from that of controls. Glutamate (1 mM) induces normal phase-shifts,
but PAI-1 (0.5 uM) does not block these phase-shifts in SCN brain slices
prepared from VN-/- mice. Conversely, 2-antiplasmin (0.05 uM) continues to
block glutamate-induced phase-shifts in these slices. 2-Antiplasmin alone
induced a small but significant phase advance. One-way ANOVA indicated a
significant effect of the treatments (F6,21= 38.65). *Phaseshifts significantly
different from control (no treatment) slices based on post hoc (Dunnett’s) test (p
< 0.05). ZT, Zeitgeber time.
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PAI-1 is expressed in the brain following trauma (Ahn et al., 1999; Dietzmann et
al., 2000; Salles & Strickland, 2002), and expression has also been reported in
some areas, including the hypothalamus, under non-traumatized conditions (Hino
et al., 2001). Rhythmic expression of PAI-1 mRNA has been detected in the SCN
using microarrays, with peak expression in the early subjective night. Our data
are consistent with these findings, in that we detect PAI-1 protein in the SCN in
our brain slices at ZT16. It will be important to determine whether similar levels of
PAI-1 protein are seen in the SCN in vivo, and if the expression is rhythmic.
Regardless of whether PAI-1 expression varies across the circadian cycle, its
presence here indicates that tPA activity in the SCN is under inhibitory control.
PAI-1 also has been shown to inhibit glutamate-associated synaptic plasticity
in cultured hippocampal neurons (Neuhoff et al., 1999). While this likely involves
inhibition of tPA activity, the mechanism for this effect has not been delineated.
Thus, our results are the first to demonstrate a functional interaction between
PAI-1 and tPA in the SCN, where they play a critical role in modulating photic
phaseresetting of the SCN clock.
Previous work indicates that tPA can act through both plasmin dependent and
-independent mechanisms (Arroyo De Prada et al., 2002; Yepes et al., 2003;
Fernandez-Monreal et al., 2004; Matys et al., 2004; Kumada et al., 2005; Pawlak
et al., 2005). Therefore, we designed our experiments to explicitly test for a role
of the plasminogen activation cascade in the SCN. Our data demonstrate that
tPA acts in the SCN through conversion of plasminogen to plasmin. First, we
show that plasminogen protein is expressed in the SCN. Second, co-application
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of plasmin with PAI-1 prevents PAI-1 inhibition of glutamate-induced phase-shifts,
while co-application of plasminogen does not. Third, co-application of 2antiplasmin inhibits glutamate-induced phase-shifts. The inhibition by 2antiplasmin is dose-dependent, with an ED50 about 10 nM, corresponding to its
concentration in the plasma (Collen & Wiman, 1978; Cederholm- Williams, 1981).
These results are consistent with studies in the hippocampus showing that
plasmin rescues a LTP deficit seen in tissue obtained from tPA-/- mice, while
application of plasminogen to tPA-/- slices has no effect (Pang et al., 2004).
Furthermore, this work establishes a role for plasmin in BDNF activation in the
SCN that is similar to the interaction between plasmin and BDNF that has been
demonstrated in the hippocampus. In vitro experiments in the hippocampus show
that plasmin cleaves proBDNF to generate mBDNF (Pang et al., 2004). Pang et
al. (2004) also report that treating plasminogen-/- slices with mBDNF reinstates
their capacity to generate LTP, whereas treating BDNF+/- slices with plasmin
does not rescue LTP. This work further documented that neither tPA nor
plasminogen alone is capable of cleaving proBDNF to form mBDNF. Treating
slices with tPA and plasminogen, however, is as effective as plasmin in
generating mBDNF. These findings indicate that in the hippocampus, tPA affects
proBDNF cleavage indirectly by activating plasmin. In a similar fashion, our
experiments show that exogenous mBDNF restores the glutamate-induced
phase-shifts that are inhibited by 2-antiplasmin. Importantly, we also find that 2antiplasmin treatment decreases mBDNF levels in the SCN.
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Several studies have demonstrated that BDNF is necessary for photic phaseshifts of the SCN circadian clock. BDNF+/- mice have reduced light-induced
phase-shifts, and blocking TrkB receptors prevents light- and glutamate-induced
phase-shifts in vivo and in vitro, respectively (Liang et al., 2000; Michel et al.,
2006). There are circadian rhythms in BDNF protein and mRNA expression in the
SCN, with peak levels at night, when glutamate and light are capable of phaseshifting the clock (Liang et al., 1998, 2000). These studies did not establish,
however, whether the rhythmic protein corresponds to proBDNF, mBDNF, or a
combination of both. It is also not clear whether there is a rhythm in BDNF
release in the SCN. In the hippocampus, most proBDNF appears to be converted
to mBDNF extracellularly (Lee et al., 2001). Our data showing a decrease in
mBDNF levels after 2-antiplasmin treatment suggest that, as in the
hippocampus, proBDNF is converted to mBDNF extracellularly through
proteolytic cleavage by plasmin.
Our data further support the idea that mBDNF acts as a gating molecule for
photic phase-resetting. Similar to in vivo results using chronic BDNF infusions,
we show that acute application of BDNF to SCN brain slices allows glutamate to
induce TrkB-dependent phase shifts in the subjective day. These data suggest
that all the cellular components necessary for glutamate-induced phase-shifts
downstream from mBDNF are available throughout the 24-h cycle. Adding
mBDNF in the day allows glutamate to generate phase-shifts, while preventing
mBDNF production at night prevents the phase-shifts. Our finding that cotreatment with tPA and glutamate is also able to phase advance the SCN
45

circadian clock suggests that there may be sufficient pro-BDNF available in the
SCN during the daytime, but that the amount of active tPA is limited.
Because of the close association of VN and PAI-1 in many physiological
scenarios, we investigated the role of VN related to the plasminogen cascade
and its effects in the SCN. Very little is known about the actions of VN in the adult
brain. VN is primarily produced in the liver (Seiffert et al., 1994; Seiffert, 1997);
however, VN mRNA expression has also been shown in the brain, e.g. in the
meninges and in close proximity to brain capillaries (Seiffert et al., 1996). Our
results extend the current understanding to indicate that VN protein is found in
the SCN. These results are consistent with previous microarray data showing VN
mRNA expression in SCN2.2 cells, a line of immortalized SCN cells derived from
rats (Menger et al., 2005).
In the periphery, VN is usually associated with the extracellular matrix, where it
binds to multiple proteins. Through interactions with integrins, VN modulates cell
migration and growth (Isahara & Yamamoto, 1995; Kjoller et al., 1997). Through
its interaction with PAI-1, VN maintains PAI-1 in its active form (Podor et al.,
2000a,b; Minor & Peterson, 2002), such that it can effectively inhibit tPA. The fact
that SCN electrical activity rhythms in tissue from VN-/- mice peak at the normal
time in vitro indicates that the SCN clock in these mice does not exhibit marked
deficits in photic entrainment. Together, these data are consistent with VN acting
in the SCN to stabilize and/or localize PAI-1. Disrupting the interaction of VN with
PAI-1 thus appears to decrease the inhibitory regulation of tPA, which if anything
should enhance SCN responsiveness to photic-entraining signals. The VN ⁄PAI-1
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interaction appears to play an active role in the SCN, as PAI-1 does not block
glutamate-induced phase-shifts in SCN brain slices obtained from VN-/- mice.
This result is not due to an inactivation of the tPA-plasmin pathway in the SCN of
VN-/- mice, as 2-antiplasmin inhibits glutamate-induced phase-shifts in VN-/brain slices. These results are some of the first to demonstrate a role for VNmediated effects of PAI-1 in the adult brain. In particular, they are consistent with
VN acting in the SCN to maintain PAI-1 in its active form, allowing PAI-1 to inhibit
the glutamate signal-enhancing actions of tPA. Whether the lack of VN alters
other entrainment processes in the SCN is an issue that will need to be explored
in future experiments.
It is unclear how much attention should be paid to the small phase advance
induced by 2-antiplasmin applied to VN-/- brain slices. 2-Antiplasmin treatment
did not induce a significant effect when applied to wild-type brain slices. It is
possible that the lack of VN changes SCN neurochemistry enough so that there
is an increase in basal plasmin activity, which in turn affects circadian clock
phase. This is a possibility that can be explored more thoroughly in the future.
Taken together, these results demonstrate the presence of VN, PAI-1, tPA,
plasminogen and plasmin in the SCN, and suggest that they interact to regulate
photic-resetting of the SCN circadian clock. The results support the hypothesis
that these proteins regulate the conversion of proBDNF to mBDNF in the SCN,
and that mBDNF availability acts as a gating mechanism for photic phaseresetting. It is noteworthy that these proteins generally interact extracellularly,
often bound to the extracellular matrix (Sappino et al., 1993; Carmeliet & Collen,
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1998; Minor & Peterson, 2002). As such, the consideration of processes that
modulate SCN circadian clock phase-resetting should be expanded to include
extracellular as well as intracellular mechanisms. These findings lay the
groundwork for future investigations into the functions of these proteins in the
brain and, in particular, their roles in modulating the SCN circadian clock.
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CHAPTER III
Endogenous and Glutamate-Modulated Fibrinolytic Protein and
BDNF Expression in the Mouse Suprachiasmatic Nucleus in
vitro

Abstract
Mammalian circadian rhythms are controlled by a clock located in the
suprachiasmatic nucleus (SCN). The mechanisms through which light phaseshifts the SCN circadian clock are similar to those underlying memory formation
and long-term potentiation (LTP). Several secreted proteins, including tissue-type
plasminogen activator (tPA), plasminogen, and brain-derived neurotrophic factor
(BDNF), have been implicated in this process.

These same proteins are

important for photic phase-shifts of the SCN circadian clock. We have shown that
tPA, plasmin and BDNF modulate glutamate-induced phase shift in mouse SCN
in vitro. tPA and plasmin may interact to convert pro-BDNF into m(ature) BDNF.
We have further shown that the endogenous tPA inhibitor, plasminogen activator
inhibitor 1(PAI-1), associated with vitronectin, contributes to these processes.
Here we used western-blot analyses of SCN tissue maintained in vitro to assay
the expression patterns of BDNF and fibrinolytic proteins. We find higher tPA,
plasmin and mBDNF levels in the SCN at night vs. the day. Also, in vitro
glutamate treatment of SCN tissue during early night increases tPA levels to ~2.5
times control levels, while similar treatments during late night and mid-day do not
alter tPA expression. Glutamate treatment in the early night does not alter PAI-1,
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plasmin and BDNF levels. However, co-treatment with glutamate and PAI-1
decreases plasmin levels (vs. glutamate treatment alone), while co-treatment
with glutamate and 2-antiplasmin decreases the amount of pro- and mBDNF in
the SCN relative to glutamate treatment alone. We also show that mBDNF levels
are significantly lower in tPA knockout mice during both day and night. Together,
these results support circadian clock modulation of BDNF and fibrinolytic protein
levels in the SCN. They also suggest that glutamate modulates tPA expression in
the SCN, while tPA and plasmin modulate BDNF expression. Overall, these data
are consistent with the hypothesis that tPA and its associated fibrinolytic proteins
contribute to photic phase resetting of the SCN circadian clock through
modulating the activity of BDNF.

Introduction
Synchronization of the mammalian circadian clock located in the SCN to the
environment occurs largely through photic signaling resulting in glutamate
release in the SCN, which activates N-methyl-D-aspartate (NMDA) receptors,
increases postsynaptic Ca2+ influx and activates of nitric oxide synthase (Ding et
al., 1994). In order for glutamate to phase-shift the clock, the growth factor, brainderived neurotrophic factor (BDNF), must concurrently activate its TrkB receptors
(Liang, et al. 1998, 2000; Michel, et al. 2006; Mou, et al. 2009). Light- and
glutamate-induced phase-shifts are blocked by a TrkB receptor antagonist and

50

light-induced phase shifts are substantially attenuated in BDNF+/- mice (Liang et
al., 2000; Michel et al., 2006).
Research in the hippocampus has shown that activation of BDNF involves the
fibrinolytic proteins, tissue-type plasminogen activator (tPA) and plasminogen.
tPA is an extracellular serine protease that is expressed and secreted in the
hippocampus in response to glutamate stimulation (Shin et al., 2004). The
specific downstream target of tPA proteolysis is the zymogen plasminogen. tPA
converts plasminogen to its active form, plasmin, through proteolytic cleavage
(Plow et al., 1995). Plasmin then cleaves proBDNF to form mBDNF (Lee et al.,
2001). The tPA-plasmin-BDNF axis has been implicated in the modulation of
hippocampal synaptic plasticity. Plasminogen+/- mice exhibit severely impaired
hippocampal LTP that can be rescued by application of mBDNF but not proBDNF
(Pang et al., 2004). Importantly, it also has been shown that the tPA-plasminBDNF axis modulates glutamate-induced phase-shifts in the SCN (Mou et al.
2009).
In plasma, tPA cleavage of plasminogen is countered by the serine protease
inhibitor (serpin), plasminogen activator inhibitor-1 (PAI-1; Huntington & Carrell,
2001). PAI-1 is maintained in its active state by binding with vitronectin (VN;
Podor et al., 2000a, b; Minor & Peterson, 2002; Mayasundari et al., 2004).
Functional interactions between PAI-1 and VN have been suggested in adult
mouse SCN: PAI-1 does not inhibit glutamate-induced phase shifts in SCN of
VN-/- mice as it does in wild type mice (Mou et al. 2009). These data suggest that
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tPA and plasmin modulate glutamate-induced phase-shifts in the SCN in a PAI1/VN-dependent fashion.
Previous microarray studies have found that VN, PAI-1, tPA and plasminogen
mRNA are expressed in the SCN (Panda et al. 2002; Menger et al. 2005), with
tPA and PAI-1 mRNA showing rhythmic expression (Panda et al. 2002; Menger
et al. 2005). However, the expression patterns of their respective proteins were
not investigated. Liang et al. (1998) demonstrated that SCN content of both
BDNF mRNA and protein oscillate in a circadian fashion. BDNF mRNA and
protein levels reach peak values during the early subjective day and during the
subjective night, respectively. However, in that study, they did not differentiate
between proBDNF and mBDNF. Recent studies have illuminated the functional
distinctions between proBDNF and its cleavage product, mBDNF (see review by
Lu et al. 2003). Therefore, in this study we investigate the temporal expression
patterns of these proteins, including differential analysis of pro- and mBDNF. We
also began investigating the regulation of these proteins in the SCN.

Materials and Methods
Brain slice preparation
Coronal brain slices (500 um) containing just the SCN and underlying optic
chiasm were prepared during the early subjective day from adult male (> 8 weeks
old) C57BL/6J (Harlan Laboratories) and tPA knockout (tPA-/-) mice housed in a
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12 : 12 h light : dark cycle. tPA-/- mice were kindly provided by Dr Mintz at Kent
State University. They were purchased from The Jackson Laboratory and are on
a pure C57BL/6J background. tPA-/- mice develop normally; they are fertile and
have a normal life span. There are no gross histological abnormalities. Mice were
killed by decapitation. The slices were maintained at the interface of a Hattonstyle brain slice chamber continuously perfused at 37°C with oxygenated (95%
O2/5% CO2) Earle’s Balanced Salt Solution supplemented with glucose,
bicarbonate and gentamicin. The pH was adjusted to 7.4 (Prosser, 2003). One
mouse was used for each experiment, with replicate experiments performed on
brain slices from different mice. All experimental protocols were approved by the
University of Tennessee Knoxville Institutional Animal Care and Use Committee.

Drug treatments
All treatments were bath-applied on the first day in vitro. To apply the treatments,
perfusion of the brain slice chamber was stopped, and the medium in the
chamber was replaced with medium containing the appropriate compounds.
Glutamate application was for 10 min, beginning at Zeitgeber time 6, 16 or 23
(ZT6, ZT16 or ZT23, where ZT0 corresponds to lights on and ZT12 corresponds
to lights off in the donor animal colony). In experiments involving compounds
other than glutamate, the slices were pre-treated with the other substances alone
for 30 min and then were co-treated with glutamate for 10 min. At the end of the
treatments, slices were removed and frozen in extraction buffer for later protein
analysis.
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Western blots
To assess in vivo protein expression, SCN tissue was dissected from mouse
brains as described above and immediately frozen for later Western blot assay
as described before (Mou et al. 2009). To assess in vitro protein expression,
SCN brain slices were prepared and maintained in the slice chamber for
harvesting at the appropriate time. In all cases, harvested tissue was
homogenized in ice-chilled HEPES-based extraction buffer containing a protease
inhibitor cocktail (1 mM phenylmethylsulfonyl fluoride, 10 mg/mL aprotinin, 15
mg/mL leupeptin, 10 mg/mL pepstatin). For BDNF immunoblots, tissue was
prepared

in

Tris-based

denaturing

extraction

buffer

[4M

urea,

0.02M

dithiothreitol, 0.05M Tris, pH 7.4, 2% sodium dodecyl sulfate (SDS)]. The tissue
extract sample was separated into aliquots and stored at -80°C. Protein content
of the extract was determined by the bicinchoninic acid method (BCA; Pierce).
Tissue samples were mixed with loading buffer (pH 6.8 Tris, SDS, bromophenol
blue, glycerol), and subjected to SDS–polyacrylamide gel electrophoresis
(PAGE). Proteins were electrotransferred onto nitrocellulose membranes, which
were then incubated with blocking buffer [10% solution of non-fat dry milk in
phosphate-buffered saline with Tris (PBST)]. The membranes were probed with
primary antibodies diluted in a 2.0% solution of non-fat dry milk in PBST, followed
by goat anti-rabbit horseradish peroxidase-conjugated secondary antibody at
appropriate dilutions in the same buffer. Signals were revealed by enzymecatalysed chemiluminescence (Pierce, IL, USA). The amount of protein loaded in
each lane was assessed by probing for actin or -tubulin, so all protein
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expression is reported as levels relative to actin or -tubulin. Control experiments
included running parallel lanes loaded with the corresponding native proteins
(positive controls), and probing membranes with primary antibodies preincubated with the native protein to test for cross-reactivity and to establish the
specificity of the antibody samples. Rabbit anti-plasminogen, anti-tPA, anti-PAI-1
and anti-VN antibodies were obtained from Molecular Innovations (Detroit, MI,
USA). Rabbit anti-actin and anti--tubulin antibodies were obtained from Santa
Cruz Biochemicals (Santa Cruz, CA, USA). Rabbit anti-proBDNF antibody was
obtained from Millipore (MA, USA) and rabbit anti-BDNF antibodies were from
Alomone Labs (Jerusalem, Israel).
Statistical analysis
One-way ANOVA was used to test for significant differences among protein
levels for 24 hour rhythm. . Student’s t-test was used to test differences in protein
levels between two groups. Post-hoc Tukey tests were used for multiple
comparisons among more than two groups. Significance was set at p<0.05.

Results
In vitro expression patterns of BDNF and fibrinolytic proteins in the SCN
We have shown that BDNF, VN, PAI-1, tPA and plasmin(ogen) are all expressed
in mouse SCN (Mou et al. 2009). Here we examined their temporal expression
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patterns. Brain slices containing the SCN from WT mice were prepared and
maintained in vitro. At three hour intervals, slices were removed and stored at 80°C for later homogenization and protein analysis.
We differentiated between pro- and mBDNF proteins by using respectively
specific antibodies as well as by their distinct sizes. proBDNF was identified as
~37kD bands, while mBDNF ~15kD bands. Although proBDNF levels relative to
-tubulin appear to increase during the subjective day and decrease during
subjective night, there was no statistically significant change in proBDNF levels
across time (one-way ANOVA, p=0.95, Fig. 10). Even when the data for the 4
highest time points (ZT6-ZT 18) were pooled and compared to the pooled lowest
values (ZT18-ZT6), there was no significant difference (p=0.16). Conversely,
mBDNF levels in the mouse SCN exhibited significant changes over the course
of the 24 hours (one-way ANOVA, p<0.05, Fig. 11). The SCN content of mBDNF
was low throughout the daytime, rose to a peak around ZT12, then declined
during the subjective night. Overall, there was about a 2.5 fold difference
between the minimum and maximum levels. Levels of mBDNF in the SCN pooled
across the late subjective day to subjective night (ZT11-ZT20) were significantly
greater than those pooled from the late subjective night to subjective day (ZT23ZT8) (Student’s t-test, p<0.05). To increase temporal resolution of the changes in
mBDNF levels, the data were pooled into four groups (represented by red
horizontal bars in Fig. 11). mBDNF levels during ZT11 to ZT14 were significantly
higher than those during ZT5 to ZT8 and ZT23 to ZT2 (post hoc Tukey test,
p<0.05).
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The SCN content of tPA also exhibited a fluctuation across 24 hours. tPA
levels pooled across the subjective night (ZT14-ZT24) were significantly greater
than those throughout the subjective day (ZT4-ZT12) (Student’s t-test, p<0.05,
Fig. 12).
There was also a fluctuation in the SCN content of plasmin. Plasmin levels
pooled across the subjective night (ZT14-ZT23) were significantly greater than
those throughout the subjective day (ZT0-ZT11) (Student’s t-test, p<0.05). Again,
the data were pooled into four groups as for mBDNF. Plasmin levels during ZT17
to ZT20 were significantly higher than those during ZT5 to ZT8 (post hoc Tukey
test, p<0.05, Fig. 13).
Temporal expression patterns for PAI-1 and VN, were assessed at 6 hour
intervals. As shown in Figure 14, PAI-1 levels exhibited changes across the 24
hours. Analysis of the pooled data indicated that PAI-1 levels during subjective
day (ZT5-ZT11) were greater than those during the night (ZT17-ZT23) (Student’s
t-test, p<0.05). Conversely, VN levels did not show significant changes across
the 24 hours (one-way ANOVA, p=0.57) or when the data were pooled into
highest and lowest 12-h intervals (ZT11-ZT17 vs. ZT23-ZT5; p=0.24, Fig. 15).
The protein changes observed in the SCN in vitro are summarized in Figure
16A.

As a comparison, the times of peak mRNA expression as reported in

previous studies (Liang et al., 1998; Menger et al., 2005) are shown in Figure
16B.
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Figure 10. In vitro expression of proBDNF protein in the mouse SCN. Plotted are
the protein levels relative to -tubulin at 3 hours intervals with SEM (n = 3 for
each time point). One-way ANOVA indicated no significant differences across
time (p=0.95). Post hoc Student’s t-test of samples pooled from ZT6-ZT18 vs.
ZT18-ZT6 also indicated no significant difference (p=0.16). Black horizontal bar:
lights-off in the animal colony.

58

A:

B:

mBDNF relative density

5

*

*

4

3

2

1

0
0

6

12

18

24

30

Zeitgeber time (hr)

Figure 11. In vitro expression of mBDNF protein in the mouse SCN. (A) Western
blot result of mBDNF time course. (B) Plotted are the protein levels relative to tubulin at 3 hours intervals with SEM (n = 3 for each time point). The data were
pooled into four groups, represented by red horizontal bars. *mBDNF levels
during ZT11 to ZT14 were significantly higher than those during ZT5 to ZT8 and
ZT23 to ZT2 (post-hoc Tukey test, p<0.05). Black horizontal bar: lights-off in the
animal colony.
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Figure 12. In vitro expression of tPA protein in the mouse SCN. (A) Western blot
result of tPA time course. (B) Plotted are the protein levels relative to actin at 3
hours intervals with SEM (n = 3 for each time point). The data were pooled into
two groups, represented by red horizontal bars. *tPA levels during ZT12 to ZT24
were significantly higher than those during ZT0 to ZT12 (Student’s t-test, p<0.05).
Black horizontal bar: lights-off in the animal colony.
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Figure 13. In vitro expression of plasmin protein in the mouse SCN. (A) Western
blot result of plasmin time course. (B) Plotted are the protein levels relative to
actin at 3 hours intervals with SEM (n = 3 for each time point). The data were
pooled into four groups, represented by red horizontal bars. *plasmin levels
during ZT17 to ZT20 were significantly higher than those during ZT5 to ZT8
(post-hoc Tukey test, p<0.05). Black horizontal bar: lights-off in the animal
colony.
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Figure 14. In vitro expression of PAI-1 protein in the mouse SCN. (A) Western
blot result of PAI-1 time course. (B) Plotted are the protein levels relative to actin
at 3 hours intervals with SEM (n = 3 for each time point). The data were pooled
into two groups, represented by red horizontal bars. *PAI-1 levels during ZT0 to
ZT12 were significantly higher than those during ZT12 to ZT24 (Student’s t-test,
p<0.05). Black horizontal bar: lights-off in the animal colony.
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Figure 15. In vitro expression of vitronectin protein in the mouse SCN. Plotted
are the protein levels relative to actin at 3 hours intervals with SEM (n = 3 for
each time point). One-way ANOVA indicated no significant differences across
time (p=0.57). Post hoc Student’s t-test of samples pooled from ZT11-ZT17 vs.
ZT23-ZT5 also indicated no significant difference (p=0.24). Black horizontal bar:
lights-off in the animal colony.
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Figure 16. Times of highest protein expression levels and their mRNA in the
SCN. A) Horizontal bars indicate the time spans during which the individual
proteins exhibited their highest values in our experiments. B) Horizontal bars
indicate the time spans within which individual mRNA exhibited their highest
values, as reported previously (Liang et al., 1998; Menger et al., 2005).
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In vitro modulation of SCN protein expression
We next investigated whether glutamate can modulate the expressions of tPA,
plasmin, proBDNF or mBDNF in the SCN in vitro. For these experiments, brain
slices containing the SCN were prepared and maintained in vitro. Depending on
the experiment, glutamate was either applied alone for 10 min or introduced with
other compounds at ZT6, 16 or 23. Tissue slices were then harvested for protein
analysis. Glutamate treatment in the early night (ZT16) increased tPA levels to
~2.5 times control levels (p<0.05, n=5), while treatment in the late night (ZT23)
and in the daytime (ZT6) did not significantly alter tPA expression (Fig. 17).
Glutamate treatment alone at ZT16 did not alter expression of plasmin, proBDNF
or mBDNF (Fig. 18). Interestingly, pre-treating SCN tissue for 30 min with PAI-1
followed by co-treatment with glutamate and PAI-1 at ZT16 decreased the
amount of plasmin in the SCN relative to glutamate treatment without affecting
the levels of pro- and mBDNF (Fig. 18A). Conversely, pre-treating SCN tissue for
30 min with 2-antiplasmin followed by co-treatment with glutamate and 2antiplasmin at ZT16 decreased the amount of pro- and mBDNF in the SCN
relative to glutamate-treatment alone without affecting plasmin levels (Fig 18B).

BDNF expression in the SCN of tPA knockout mice
Based on our previous research (Mou et al. 2009), we hypothesized that tPA
functions in the SCN to increase mBDNF production. Here we tested this
hypothesis by examining in vivo mBDNF and proBDNF protein expression in
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Figure 17. Effect of in vitro glutamate treatment on tPA expression in the SCN at
different times. 10 min glutamate treatment significantly increased tPA levels in
early night (ZT16) relative to control (no treatment), but not in late night (ZT23) or
in daytime (ZT6). (Student’s t-test, *p<0.05)
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Figure 18. In vitro Glutamate modulation of plasmin and BDNF expression in
SCN slices at ZT16. (A) Glutamate+PAI-1 treatment significantly decreased
plasmin expression relative to glutamate treatment alone, but did not affect the
levels of pro- and mBDNF. (B) Glutamate + 2-antiplasmin treatment decreased
the amount of pro- and mBDNF relative to glutamate treatment alone, but did not
affect plasmin levels. (Student’s t-test, * p<0.05)
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SCN tissue from tPA knockout mice (tPA-/-).
For these experiments, SCN tissue was isolated from WT and tPA-/- mice and
immediately transferred into extraction buffer for protein analysis. Based on the in
vitro circadian expression pattern of mBDNF in WT mice shown earlier, we chose
to assay pro- and mBDNF levels at two time points, ZT4 and ZT12, when
mBDNF displayed the lowest and highest levels respectively. SCN content of
pro- and mBDNF from tPA-/- and WT mice was quantified and normalized to tubulin. Then a mBDNF to proBDNF ratio was computed as the index for relative
mBDNF quantity. Comparative analysis showed that mBDNF/proBDNF levels in
WT mice were significantly higher than in tPA-/- mice at ZT4 (p<0.05) and there
was a trend towards being significantly higher at ZT12 (p=0.06) (Fig. 19).
It was noted that the in vitro rhythm in mBDNF levels, with highest expression
at ZT11, observed in WT SCN tissue (Fig. 10), was not seen in this experiment
for either WT or tPA-/- mice (data not shown). This difference could be attributed
to the difference in tissue harvesting protocol in the two experiments. In this
case, SCN tissue from tPA-/- mice was harvested immediately after slice
preparation. Another set of experiments was conducted to test this possibility.
One set of brain slices containing the SCN from WT mice was prepared at ZT1
and maintained undisturbed in the slice chamber for later harvesting and
homogenization at either ZT4 or ZT12. In parallel, a second set of slices was
prepared at ZT4 and ZT12 and harvested immediately without incubation in the
slice chamber. Protein quantities were assayed as before. As shown in Fig. 20,
mBDNF protein expression is substantially higher, although not reaching statistic
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significance, at ZT12 than at ZT4 in SCN slices maintained in vitro (p=0.06),
while mBDNF levels are essentially unchanged between ZT4 and ZT12 in SCN
tissue harvested immediately after slice preparation (p=0.30).

Discussion

Having previously demonstrated the critical involvement of tPA and its associated
proteins in glutamate-induced phase resetting of the mouse SCN circadian clock,
in this study we wished to characterize the expression patterns of these proteins.
We began by examining the in vitro temporal pattern of protein expression in the
SCN from WT mice. We found significant rhythms in PAI-1, tPA, plasmin and
mBDNF levels, while we found no rhythm in proBDNF and VN protein expression
in the SCN.
Our data on mBDNF and proBDNF are interesting in light of a previous study
investigating BDNF expression in SCN (Liang et al. 1998). In that study, BDNF
protein levels in the rat SCN (not differentiating between pro- and mBDNF) were
found to peak around CT16, while BDNF mRNA levels were shown to peak
approximately 16 hour earlier, around CT0. Our results showing high mBDNF
levels in early subjective night fit well with their data. Combined with our data
showing a lack of temporal changes in pBDNF, this suggests that the rhythmic
expression pattern of BDNF observed in their study may in fact correspond to
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Figure 19. Modulation of BDNF expressions by tPA. Shown are mBDNF to
proBDNF ratios for WT and tPA-/- mice at ZT4 and ZT12. *mBDNF/proBDNF ratio
for WT mice is higher than that for tPA-/- mice at ZT4 (p<0.05) and at ZT12
(p=0.06).
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Figure 20. Tissue harvesting protocol affects mBDNF level. Shown are mBDNF
to -tubulin ratios for WT mice at ZT4 and ZT12. *Relative mBDNF levels of
tissue maintained in vitro showed a trend towards a significant difference
(p=0.06), while those harvested without incubation did not (p=0.30).
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mBDNF. On the other hand, since proBDNF levels in our study show a trend
somewhat in parallel with that of mBDNF, we cannot rule out the possibility that
the previous study measured both mBDNF and proBDNF. Unfortunately, they do
not indicate what size protein they were quantifying, so this cannot be verified.
The circadian regulation of mBDNF expression provides an endogenous
mechanism for SCN cells to gate their sensitivity to photic/glutamate stimuli.
Elevated SCN levels of mBDNF during the subjective night coincide with the
critical time window when light and glutamate can induce phase shifts in the SCN
pacemaker. Conversely, expression of mBDNF remains at basal levels
throughout the subjective day when the SCN cells are insensitive to
light/glutamate stimuli (Ding et al., 1998; Liang et al., 2000). The potential for
mBDNF to act as a photic gating mechanism is reinforced by data showing that
chronic infusion of BDNF into the SCN allows light induced phase shift in the
subjective day (Liang et al., 2000). Likewise, daytime treatment of SCN brain
slices with glutamate and BDNF can phase-advance the SCN clock, while
glutamate treatment alone at that time normally has no resetting action (Mou et
al., 2009).
The relatively low tPA protein expression in the SCN during the daytime is also
consistent with our hypothesis that circadian clock sensitivity to photic stimuli is
modulated by mBDNF availability, and that tPA participates in regulating mBDNF
levels. These data are also consistent with our earlier results showing that cotreatment of SCN brain slices with glutamate and tPA at ZT6 induced a phase
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advance (Mou et al., 2009). Thus, daytime treatment with tPA may lead to higher
daytime BDNF levels, which then allows (gates) glutamate-induced phase shifts.
The high tPA levels we observed at night are also consistent with our results
showing: first, that plasmin protein levels are high in the SCN at night in parallel
with increased tPA levels; second, that PAI-1 treatment at ZT 16, when tPA
levels are high, decreases plasmin expression in the SCN; and third, that
nighttime treatment with PAI-1 blocks glutamate-induced phase shifts in vitro
(Mou et al. 2009). To confirm the functional nature of these changes in tPA,
however, it would be worthwhile to follow up these experiments on protein
expression with experiments investigating differences in protein activity.
A previous study has shown that tPA exhibits highest mRNA abundance
during late day (Menger et al., 2005). Our results showing that tPA protein has
higher expression during the night (Fig. 16), suggests that tPA translation follows
transcription with a few hours delay. Although tPA transcription and translation
are known to be activated by glutamate receptor stimulation (Shin et al., 2004),
additional research is needed to determine what regulates these processes in the
SCN.
In our experiments, we also observed higher PAI-1 protein expression during
the day than the night. Lower PAI-1 protein expression during the night is
consistent with higher tPA activity in the SCN during night, as could be reflected
by the higher plasmin and mBDNF levels in the SCN at night. Interestingly, a
previous study found out that PAI-1 mRNA in the SCN has its highest expression
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during early night (Panda, 2002). This suggests there may be a 12 h delay
between PAI-1 transcription and translation. Similar differences in mRNA and
protein levels are seen with other circadian clock proteins in the SCN (Liang et
al., 1998).
tPA and PAI-1 also fluctuate in a circadian manner In the periphery. PAI-1
activity in plasma is significantly higher humans in the morning, concurrent with
lower tPA activity (Angleton et al., 1989). These circadian fluctuations parallel the
higher onset of acute atherothrombotic events. For example, increased morning
PAI-1 activity in humans is associated with early morning hypofibrinolysis
(Kurnik, 1996), which could contribute to the morning onset of stroke. Our results
showing higher PAI-1 expression starting in the early morning actually are 12h
out-of-phase with these results in humans, since early morning in mice is the
onset of their inactive phase. However, there is precedence for peripheral
gene/protein expression being out-of-phase with respect to SCN expression
(Hasting et al., 2003; Schibler et al., 2003). Interestingly, PAI-1 expression is
under transcriptional regulation by the heterodimer of circadian clock genes,
Clock/Bmal, that activate E-box enhancers in the PAI-1 promoter (Schoenhard et
al., 2003). The circadian expression pattern of PAI-1 mRNA is lost in the Clock
mutant mouse (Minami et al., 2002). Thus, clock gene products may drive the
circadian variation in PAI-1 expression, which in turn can influence the timing of
fibrinolysis in the periphery, and photic phase resetting in the SCN.
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In addition to their potential regulation by the circadian clock, we also show
that tPA, plasmin and BDNF levels in the SCN can be altered by application of
endogenous modulators. Glutamate treatment increased tPA expression, but
only when applied during early night. Whether this time-dependency is due to a
lack of tPA mRNA available at other circadian times or whether other factors limit
tPA induction is not known. Conversely, the other proteins assayed (plasmin,
pro- and mBDNF) were not affected by glutamate treatment alone. It is quite
possible that these negative results are attributable to the short treatment time
frame used (10min). This brief period may have been insufficient for changes in
(tPA) protein expression to be translated into changes in downstream proteolytic
processes. Subsequent studies should be conducted to examine glutamate
effects on protein levels after longer time periods.
Following up on these results, it is interesting that a 30 min pre-treatment with
PAI-1 followed by glutamate at ZT16 decreased plasmin expression in the SCN.
These data are consistent with an ongoing tPA-induced conversion of
plasminogen to plasmin in the SCN occurring during early night that can be
inhibited by PAI-1. While pro- and mBDNF levels were not changed by this
treatment, again it is possible that changes in these proteins, being further
downstream from tPA regulation, might have been seen after a longer posttreatment period. Consistent with this possibility, decreased mBDNF expression
was observed when plasmin was directly inhibited by 2-antiplasim, an inhibitor
more proximate to proBDNF cleavage to mBDNF. On the other hand, it was
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surprising that proBDNF expression also decreased under 2-antiplasim
treatment, since the decrease in mBDNF production ought to be associated with
an increase in proBDNF levels. A more thorough analysis of the changes in
protein expression in the SCN might resolve this issue.
We also show that mBDNF/proBDNF ratios are significantly lower in tPA-/mice. These data lend further support to the hypothesis that mBDNF production
in the SCN is regulated by tPA. One might predict, based on these results, that
tPA-/- mice would exhibit deficits in photic entrainment, similar to their deficits in
hippocampal LTP, that can be reversed by either plasmin or mBNDF treatment
(Pang et al., 2004).
One important issue that remains to be addressed is whether there is a rhythm
in the secretion of BDNF and other proteins in the SCN. In general, cellular
secretion of BDNF is thought to parallel neuronal activity (Balkowiec et al., 2000;
Level et al., 2001; Luo et al., 2001; Kuczewski et al., 2009). If this were true in
the SCN, then one would see higher BDNF secretion in the day, when SCN
neuronal activity peaks. In the hippocampus, proBDNF conversion to mBDNF
appears to occur primarily extracellularly (Lee et al., 2001). Furthermore, tPA and
plasminogen are thought to be secreted from neurons in parallel with BDNF. So
the question becomes: do the rhythms in protein expression seen here reflect
rhythms in protein production, and/or rhythms in secretion? Our data showing a
decrease in mBDNF levels after 2-antiplasmin treatment suggests that, in the
SCN, proBDNF is converted to mBDNF extracellularly through proteolytic
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cleavage by plasmin. However, we still know little about the secretory dynamics
associated with the changes we have observed. This issue could be addressed
using a cell culture system where intracellular and extracellular protein
expression can be assessed separately.
Finally, as mentioned earlier, the experiments presented here do not address
the critical issue of potential rhythms in protein activity. While one can speculate
that activity rhythms will parallel those of the proteins, the existence of multiple
modulations associated with these proteins make such speculation somewhat
tentative.
Taken together, these results provide support for circadian clock regulation of
BDNF, tPA, plasmin, and PAI-1, but not VN protein expression in the mouse
SCN. They further suggest that glutamate modulates tPA expression in the SCN
during early night, tPA modulates plasmin production, and plasmin in turn
modulates mBDNF expression. Together, these results are consistent with the
hypothesis that the tPA/plasmin axis functions in the SCN to activate BDNF,
thereby gating the ability of the SCN clock to be modulated by photic input.
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CHAPTER IV
Conclusions and Future Directions
A Working Model for Glutamate-induced Phase Shifts in mouse
SCN
Based on our results in chapter 2 and 3, a working model for glutamate-induced
phase shifts in the SCN was created and illustrated in Fig. 21. Vitronectin and
plasminogen expressions do not display significant rhythmic patterns throughout
24 hours. Given high PAI-1 levels and low tPA level during the day, plasmin and
mBDNF cannot be converted from their respective precursors in sufficient
quantity. Without enough mBDNF activating its TrkB receptors, enhancement of
glutamate activity cannot occur, therefore no glutamate-induced phase shifts will
take place during daytime (Fig. 21A). However, adding exogenous tPA or
mBDNF during the day can overcome these insufficiencies, thereby allowing
daytime phase shifts by glutamate.
Conversely, tPA levels are high during night and PAI-1 levels are low. This
combination allows increased production of plasmin and mBDNF. The increased
mBDNF production activates TrkB receptor , which enhances glutamate signaling
and allows glutamate- induced phase shifts (Fig. 21B).

BDNF Could Regulate the Expression/activity of NMDA
Receptors
BDNF has been shown to play multiple important roles in NMDA receptormediated hippocampal LTP (reviewed in Bramham and Messaoudi, 2005). The
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A: Day: low tPA, plasmin, and mBDNF levels

B: Night: high tPA, plasmin, and mBDNF levels

Figure 21. Model of extracellular gating of photic phase resetting of the SCN
circadian clock. A: high PAI-1 and low tPA during the day result in low mBDNF
generation, therefore no glutamate phase shifts are induced. B: Glutamateinduced phase shifts are induced during night when tPA activity is not inhibited
by PAI-1, which leads to higher mBDNF production
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rapid effects of BDNF on postsynaptic responses to glutamate have been largely
attributed to phosphorylation of NMDA receptor subunits, which increases
receptor activity (Levine et al. 1998; Levine and Kolb, 2000). This effect may
involve BDNF-TrkB-Src like kinases.
BDNF may also alter the availability of NMDA receptor subunits. Caldeira et al.
(2007) showed that in a hippocampal cell culture system, BDNF induces a rapid
delivery of NR2B-containing NMDA receptors to the plasma membrane, which
correlates with an increase in intracellular Ca2+ concentration. They also showed
that BDNF increases mRNA levels for NR1, NR2A and NR2B subunits. Given the
abundance of BDNF and TrkB receptors in the SCN, and their colocalization with
NMDA receptors, it would not be surprising if BDNF upregulates NMDA receptor
phosphorylation and/or expression in the SCN. In vitro immunohistochemistry
could be used to address this question.
Given the demonstrated importance of BDNF for LTP, one question is where
the BDNF is coming from. Marini et al. (1998) showed that in cerebellar granule
cell culture, exposure of granule cells to NMDA evoked an accumulation of BDNF
in the medium without concomitant changes in the intracellular levels of BDNF
protein or mRNA. The increase in BDNF in the medium was followed by
enhanced TrkB tyrosine phosphorylation. This coactivation of NMDA and TrkB
receptors can occur within ten minutes. This time-course is consistent with
BDNF’s importance for the initial stage of LTP. It is not clear whether NMDA
receptor activation induces BDNF release in SCN. If it does, a mutual facilitation
between glutamate/NMDA and BDNF/TrkB signaling could amplify the effects
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exerted by each acting alone. Using cell culture could help reveal changes in
extracellular vs. intracellular BDNF levels.

BDNF Effects on Presynaptic Cells
In our model, BDNF facilitates photic/glutamate induced phase shifts in the
SCN by enhancing the signaling of postsynaptic NMDA receptors. However, the
facilitating effects of BDNF are not limited to postsynaptic cells. In the visual
cortex and hippocampus, BDNF can also potentiate neuronal signaling by
enhancing transmitter release from presynaptic neurons (Levine et al., 1995;
Carmignoto et al., 1997; Tanaka et al., 1997). BDNF could likewise modulate
responses of SCN neurons to photic input via enhancing presynaptic release of
neurotransmitter from RHT terminals. Evidence for this comes from a study
showing that BDNF enhances spontaneous excitatory postsynaptic potentials in
SCN cells in vitro (Michel et al. 2006). However, given that BDNF treatment
alone during the day does not induce a phase shift (Liang et al., 2000; Mou et al.,
2009), this indicates that the amount of glutamate released in response to BDNF
is insufficient to alter clock phase.
BDNF could also act in the SCN through modulating GABA neurotransmission.
BDNF has been shown to attenuate the responses of GABA receptors to GABA
applied to rat hippocampal neurons (Tanaka et al., 1997). Since GABA is the
predominant neurotransmitter in the SCN (Moore and Speh, 1993; Liu et al.,
1994), and GABAergic agents alter the phase-shifting effects of light on circadian
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rhythms (Ralph and Menaker, 1989; Golombek and Ralph, 1994), BDNF could
act via the GABAergic transmission system to regulate photic resetting of the
SCN pacemaker. Experiments investigating SCN phase shifts when BDNF and
GABA are coapplied could address this question.

BDNF mRNA Alternatives
Like other neuropeptides, BDNF is synthesized as a pre-proprotein that
undergoes further splicing and modification at multiple steps. While not
distinguished in our study, multiple BDNF transcripts exist. Mouse and rat BDNF
genes consist of four 5’ noncoding exons (I, II, III, or IV) and one protein coding
3’ exon. Transcription of the gene results in BDNF transcripts containing one of
the four 5’ exons spliced and the 3’ protein coding exon. BDNF gene expression
is controlled by multiple activity-dependent and tissue-specific promoters. Four
BDNF promoters have been previously identified in rat (Timmusk et al., 1993;
Timmusk et al., 1995), each driving the transcription of BDNF mRNAs containing
one of the four 5’ noncoding exons spliced to the common 3’ coding exon. In
addition,

transcription

factors,

such

as

CREB

and

calcium-responsive

transcription factor (CaRF), have been found to modulate BDNF transcription
through binding to different BDNF promoters (Tao et al., 1998; Tabuchi et al.,
2002; Tao et al., 2002). Chromatin remodeling by DNA methylation and histone
deacetylation also plays an important role in cell-specific and activity-dependent
regulation of BDNF (Timmusk et al., 1999; Zuccato et al., 2003). Because
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alterations in BDNF expression in specific neuron subpopulations contribute to
various nervous system pathologies, including depression, epilepsy, and
Alzheimer’s, Huntington’s, and Parkinson’s diseases (Bibel and Barde, 2000;
Binder and Scharfman, 2004; Castren, 2004; Russo-Neustadt and Chen, 2005),
it would be interesting to determine which BDNF transcript(s) are involved in
circadian clock resetting in the SCN.

Localization of Fibrinolytic Proteins and Their Activity
From the data presented earlier, it is clear that fibrinolytic proteins regulate
the generation of mBDNF, and thus modulate glutamate-induced SCN clock
resetting. However, the localization and compartmental distribution of those
proteins within the SCN remains unclear. The mechanisms through which
fibrinolytic proteins exert their activities can vary depending on their localization
and binding partners. For example, in addition to regulating plasmin generation,
the VN-PAI-1 complex interacts with extracellular matrix (ECM) proteins. Through
this interaction, VN localizes PAI-1 to specific extracellular loci to modulate
migration and proliferation. However, there has been little investigation into the
location of VN and PAI-1 in the brain. Likewise, tPA and plasmin localization and
activity in the brain is largely uncharacterized, in particular as to whether their
localization and/or activity are altered by neuronal stimulation.
The best system to investigate the compartmental location of the fibrinolytic
proteins and their activity is one where the cells, extracellular fluid and ECM can
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be separated. The SCN2.2 cell line is such a system to achieve this goal. This
immortalized cell line has been studied extensively in the mammalian circadian
system. These cells express many of the functional characteristics of the intact
SCN, they generate circadian rhythms, and they respond to phase-resetting
stimuli found to reset the intact SCN (Allen and Earnest, 2002; Rivera-Bermudez
et al., 2003; Menger et al., 2005; Nahm et al., 2005). Recently, we have shown
in our lab that all the fibrinolytic proteins and BDNF are expressed within all three
tissue compartments (cells, medium, and ECM) in the SCN2.2 cell culture
(abstract, Cantwell et al., 2008). The next step is to determine the temporal and
spacial distribution of their enzymatic activities, and determine which fibrinolytic
protein binding partners are critically involved in regulating BDNF activity.

Plasmin-independent Effects of tPA
In addition to activating plasmin, many tPA effects in the central nervous
system are plasmin-independent. One molecule with which tPA directly interacts
to enhance LTP is the NR1 subunit of the NMDA receptor. Using a neuronal cell
culture model, Nicole et al. (2001) reported that tPA cleaves NR1, thereby
enhancing

NMDA-mediated

intracellular

calcium

levels

and

neuronal

degeneration. However, the direct cleavage of NR1 by tPA has not been
observed in other studies (Matys and Strickland, 2003; Liu et al., 2004). An
interaction between tPA and the NR2B subunit has been reported during ethanol
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withdrawal-induced seizures (Pawlak et al. 2005). In the amygdala, the function
of tPA during stress-induced anxiety also seems to be independent of plasmin
production (Pawlak et al. 2003). These lines of evidence suggest that tPA can
function either as a protease or a modulator of cell signaling, and that PAI-1 can
influence both of these activities. Whether plasmin-independent effects of tPA
occur in the SCN has not been investigated.

Neuroserpin
As mentioned earlier, neuroserpin is an inhibitor of tPA found exclusively in the
central nervous system. The degree to which tPA is regulated by neuroserpin vs.
PAI-1 in the brain has not been investigated. In the adult nervous system,
neuroserpin is detected in neurons in the same places where tPA is detected,
such as hippocampus, hypothalamus, cerebellum, amygdala, and sympathetic
nerves (Krueger, 1997).
Neuroserpin has been suggested to play a variety of roles in the CNS. It is
rapidly released from cells in response to neuronal depolarization, indicating the
presence of a storage pool that, as with tPA, is ready to be released in response
to stimuli (Yepes and Laurence, 2004). In vitro studies have shown an activitydependent upregulation of neuroserpin in the hippocampus (Berger et al., 1999).
Animals either lacking or over-expressing neuroserpin exhibit reduced locomotor
activity in novel environments and anxiety-like responses (Madani et al. 2003). In
mice, neuroserpin plays a critical role in the development of the primary visual
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cortex (Wannier-Morino et al., 2003). Early after the onset of cerebral ischemia,
there is a transient increase in tPA activity, followed by a surge in neuroserpin in
the ischemic area (Yepes et al., 2000; 2004). Also, neuronal depolarization
results in secretion of tPA and an increase in the neuronal transcription of
neuroserpin (Berger et al., 1999).
Neuroserpin reacts ~30-fold slower with tPA than does PAI-1 (Hastings et al.,
1997). Nevertheless, given its general co-expression with tPA in the brain, it
would be interesting to investigate its role in regulating the SCN clock.
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